Publications published since 2000 from OUS - Department of Gynaecological Oncology

391 publications found

Publications 2020

  1. Fjeldbo CS, Hompland T, Hillestad T, Aarnes EK, Günther CC, Kristensen GB, Malinen E, Lyng H (2020)
    Combining imaging- and gene-based hypoxia biomarkers in cervical cancer improves prediction of chemoradiotherapy failure independent of intratumour heterogeneity
    EBioMedicine, 57, 102841
    DOI 10.1016/j.ebiom.2020.102841, PubMed 32580139
  2. Harter P, Pautier P, Van Nieuwenhuysen E, Reuss A, Redondo A, Lindemann K, Kurzeder C, Petru E, Heitz F, Sehouli J, Degregorio N, Wimberger P, Burges A, Cron N, Ledermann J, Lorusso D, Paoletti X, Marme F (2020)
    Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer - a randomized phase III trial (AGO-OVAR 2.29/ENGOT-ov34)
    Int J Gynecol Cancer (in press)
    DOI 10.1136/ijgc-2020-001572, PubMed 32606097
  3. Hillestad T, Hompland T, Fjeldbo CS, Skingen VE, Salberg UB, Aarnes EK, Nilsen A, Lund KV, Evensen TS, Kristensen GB, Stokke T, Lyng H (2020)
    MRI Distinguishes Tumor Hypoxia Levels of Different Prognostic and Biological Significance in Cervical Cancer
    Cancer Res, 80 (18), 3993-4003
    DOI 10.1158/0008-5472.CAN-20-0950, PubMed 32606004
  4. Kargo AS, Coulter A, Lindemann K, Jensen PT, Hjøllund NH, Mosgaard BJ, Steffensen KD (2020)
    Use of PROM during follow-up of patients with ovarian cancer: the PROMova study protocol
    Int J Gynecol Cancer, 30 (9), 1444-1449
    DOI 10.1136/ijgc-2020-001528, PubMed 32586892
  5. Koklesova L, Liskova A, Samec M, Qaradakhi T, Zulli A, Smejkal K, Kajo K, Jakubikova J, Behzadi P, Pec M, Zubor P, Biringer K, Kwon TK, Büsselberg D, Sarria GR, Giordano FA, Golubnitschaja O, Kubatka P (2020)
    Genoprotective activities of plant natural substances in cancer and chemopreventive strategies in the context of 3P medicine
    EPMA J, 11 (2), 261-287
    DOI 10.1007/s13167-020-00210-5, PubMed 32547652
  6. La Russa M, Zapardiel I, Zalewski K, Laky R, Dursun P, Sukhin V, Lindquist D, Lindemann K (2020)
    Assessment of palliative care training in gynaecological oncology: a survey among European Network of Young Gynae-Oncologists (ENYGO) members
    BMJ Support Palliat Care (in press)
    DOI 10.1136/bmjspcare-2020-002233, PubMed 32958506
  7. Lindemann K (2020)
    Systematic treatment of primary and recurrent cervical cancer
    Int. J. Gynecol. Cancer, 30 1, 15
  8. Lindemann K, Martinsson L, Kaasa S, Lindquist D (2020)
    Elderly gynaecological cancer patients at risk for poor end of life care: a population-based study from the Swedish Register of Palliative Care
    Acta Oncol, 59 (6), 636-643
    DOI 10.1080/0284186X.2020.1744717, PubMed 32238040
  9. Lund KV, Simonsen TG, Kristensen GB, Rofstad EK (2020)
    DCE-MRI of locally-advanced carcinoma of the uterine cervix: Tofts analysis versus non-model-based analyses
    Radiat Oncol, 15 (1), 79
    DOI 10.1186/s13014-020-01526-2, PubMed 32293487
  10. Mirza MR, Benigno B, Dørum A, Mahner S, Bessette P, Barceló IB, Berton-Rigaud D, Ledermann JA, Rimel BJ, Herrstedt J, Lau S, du Bois A, Herráez AC, Kalbacher E, Buscema J, Lorusso D, Vergote I, Levy T, Wang P, de Jong FA, Gupta D, Matulonis UA (2020)
    Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial
    Gynecol Oncol (in press)
    DOI 10.1016/j.ygyno.2020.09.006, PubMed 32981695
  11. Monk BJ, Grisham RN, Banerjee S, Kalbacher E, Mirza MR, Romero I, Vuylsteke P, Coleman RL, Hilpert F, Oza AM, Westermann A, Oehler MK, Pignata S, Aghajanian C, Colombo N, Drill E, Cibula D, Moore KN, Christy-Bittel J, Del Campo JM, Berger R, Marth C, Sehouli J, O'Malley DM, Churruca C et al. (2020)
    MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum
    J Clin Oncol, JCO2001164 (in press)
    DOI 10.1200/JCO.20.01164, PubMed 32822286
  12. Norell CH, Butler J, Farrell R, Altman A, Bentley J, Cabasag CJ, Cohen PA, Fegan S, Fung-Kee-Fung M, Gourley C, Hacker NF, Hanna L, Høgdall CK, Kristensen G, Kwon J, McNally O, Nelson G, Nordin A, O'Donnell D, Schnack T, Sykes PH, Zotow E, Harrison S (2020)
    Exploring international differences in ovarian cancer treatment: a comparison of clinical practice guidelines and patterns of care
    Int J Gynecol Cancer (in press)
    DOI 10.1136/ijgc-2020-001403, PubMed 32784203
  13. Paoletti X, Lewsley LA, Daniele G, Cook A, Yanaihara N, Tinker A, Kristensen G, Ottevanger PB, Aravantinos G, Miller A, Boere IA, Fruscio R, Reyners AKL, Pujade-Lauraine E, Harkin A, Pignata S, Kagimura T, Welch S, Paul J, Karamouza E, Glasspool RM, Gynecologic Cancer InterGroup (GCIG) Meta-analysis Committee (2020)
    Assessment of Progression-Free Survival as a Surrogate End Point of Overall Survival in First-Line Treatment of Ovarian Cancer: A Systematic Review and Meta-analysis
    JAMA Netw Open, 3 (1), e1918939
    DOI 10.1001/jamanetworkopen.2019.18939, PubMed 31922558
  14. Ramirez PT, Chiva L, Eriksson AGZ, Frumovitz M, Fagotti A, Gonzalez Martin A, Jhingran A, Pareja R (2020)
    COVID-19 Global Pandemic: Options for Management of Gynecologic Cancers
    Int J Gynecol Cancer, 30 (5), 561-563
    DOI 10.1136/ijgc-2020-001419, PubMed 32221023
  15. Ramirez PT, Pareja R, Eriksson AGZ, Frumovitz M (2020)
    International Gynecologic Cancer Society 2019 meeting summary
    Int J Gynecol Cancer, 30 (2), 167-173
    DOI 10.1136/ijgc-2019-001146, PubMed 32029483
  16. Rolfsen ALD, Dahl AA, Pripp AH, Dørum A (2020)
    Base rate of ovarian cancer on algorithms in patients with a pelvic mass
    Int J Gynecol Cancer (in press)
    DOI 10.1136/ijgc-2020-001416, PubMed 32699016
  17. Salminen L, Nadeem N, Rolfsen AL, Dørum A, Laajala TD, Grènman S, Hietanen S, Heinosalo T, Perheentupa A, Poutanen M, Bolstad N, Carpén O, Lamminmäki U, Pettersson K, Gidwani K, Hynninen J, Huhtinen K (2020)
    Exploratory Analysis of CA125-MGL and -STn Glycoforms in the Differential Diagnostics of Pelvic Masses
    J Appl Lab Med, 5 (2), 263-272
    DOI 10.1093/jalm/jfz012, PubMed 32445385
  18. Samec M, Liskova A, Koklesova L, Samuel SM, Zhai K, Buhrmann C, Varghese E, Abotaleb M, Qaradakhi T, Zulli A, Kello M, Mojzis J, Zubor P, Kwon TK, Shakibaei M, Büsselberg D, Sarria GR, Golubnitschaja O, Kubatka P (2020)
    Flavonoids against the Warburg phenotype-concepts of predictive, preventive and personalised medicine to cut the Gordian knot of cancer cell metabolism
    EPMA J, 11 (3), 377-398
    DOI 10.1007/s13167-020-00217-y, PubMed 32843908
  19. Stastny I, Zubor P, Kajo K, Kubatka P, Golubnitschaja O, Dankova Z (2020)
    Aberrantly Methylated cfDNA in Body Fluids as a Promising Diagnostic Tool for Early Detection of Breast Cancer
    Clin Breast Cancer (in press)
    DOI 10.1016/j.clbc.2020.05.009, PubMed 32792225
  20. Vistad I, Lindemann K, Bentzen AG, Dahl AA, Steen R, Kiserud C (2020)
    Preferences for follow up in long-term survivors after cervical cancer
    Acta Obstet Gynecol Scand, 99 (9), 1253-1259
    DOI 10.1111/aogs.13855, PubMed 32232835
  21. Zubor P, Dankova Z, Kolkova Z, Holubekova V, Brany D, Mersakova S, Samec M, Liskova A, Koklesova L, Kubatka P, Bujnak J, Kajo K, Mlyncek M, Giordano FA, Golubnitschaja O (2020)
    Rho GTPases in Gynecologic Cancers: In-Depth Analysis toward the Paradigm Change from Reactive to Predictive, Preventive, and Personalized Medical Approach Benefiting the Patient and Healthcare
    Cancers (Basel), 12 (5)
    DOI 10.3390/cancers12051292, PubMed 32443784

Publications 2019

  1. Binzer-Panchal A, Hardell E, Viklund B, Ghaderi M, Bosse T, Nucci MR, Lee CH, Hollfelder N, Corcoran P, Gonzalez-Molina J, Moyano-Galceran L, Bell DA, Schoolmeester JK, Måsbäck A, Kristensen GB, Davidson B, Lehti K, Isaksson A, Carlson JW (2019)
    Integrated Molecular Analysis of Undifferentiated Uterine Sarcomas Reveals Clinically Relevant Molecular Subtypes
    Clin Cancer Res, 25 (7), 2155-2165
    DOI 10.1158/1078-0432.CCR-18-2792, PubMed 30617134
  2. Eriksson AG, Fallaas Dahl G, Nesbakken AJ, Lund KV, Amant F (2019)
    Endometrial cancer during pregnancy: management strategies
    Int J Gynecol Cancer, 29 (7), 1221-1224
    DOI 10.1136/ijgc-2019-000756, PubMed 31434687
  3. Fabbro M, Moore KN, Dørum A, Tinker AV, Mahner S, Bover I, Banerjee S, Tognon G, Goffin F, Shapira-Frommer R, Wenham RM, Hellman K, Provencher D, Harter P, Vázquez IP, Follana P, Pineda MJ, Mirza MR, Hazard SJ, Matulonis UA (2019)
    Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial
    Gynecol Oncol, 152 (3), 560-567
    DOI 10.1016/j.ygyno.2018.12.009, PubMed 30638768
  4. Jonsson M, Fjeldbo CS, Holm R, Stokke T, Kristensen GB, Lyng H (2019)
    Mitochondrial Function of CKS2 Oncoprotein Links Oxidative Phosphorylation with Cell Division in Chemoradioresistant Cervical Cancer
    Neoplasia, 21 (4), 353-362
    DOI 10.1016/j.neo.2019.01.002, PubMed 30856376
  5. Lindemann K, Zalewski K, Halaska MJ (2019)
    Summary of landmark papers published between August 2018 and May 2019
    Int. J. Gynecol. Cancer, 29 1, 1-5
  6. Lund KV, Simonsen TG, Kristensen GB, Rofstad EK (2019)
    Pharmacokinetic analysis of DCE-MRI data of locally advanced cervical carcinoma with the Brix model
    Acta Oncol, 58 (6), 828-837
    DOI 10.1080/0284186X.2019.1580386, PubMed 30810443
  7. Nilsen A, Jonsson M, Aarnes EK, Kristensen GB, Lyng H (2019)
    Reference MicroRNAs for RT-qPCR Assays in Cervical Cancer Patients and Their Application to Studies of HPV16 and Hypoxia Biomarkers
    Transl Oncol, 12 (3), 576-584
    DOI 10.1016/j.tranon.2018.12.010, PubMed 30660934
  8. Piovano E, Ferrero A, Zola P, Marth C, Mirza MR, Lindemann K (2019)
    Clinical pathways of recovery after surgery for advanced ovarian/tubal/peritoneal cancer: an NSGO-MaNGO international survey in collaboration with AGO-a focus on surgical aspects
    Int J Gynecol Cancer, 29 (1), 181-187
    DOI 10.1136/ijgc-2018-000021, PubMed 30640702
  9. Roncolato F, Lindemann K, Willson ML, Martyn J, Mileshkin L (2019)
    PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer
    Cochrane Database Syst Rev (10), CD012160
    DOI 10.1002/14651858.CD012160.pub2, PubMed 31588998
  10. Vergote I, Coens C, Nankivell M, Kristensen GB, Parmar MKB, Ehlen T, Jayson GC, Johnson N, Swart AM, Verheijen R, McCluggage WG, Perren T, Panici PB, Kenter G, Casado A, Mendiola C, Stuart G, Reed NS, Kehoe S, EORTC MRC CHORUS Study Investigators (2019)
    Neoadjuvant Chemotherapy Versus Debulking Surgery in Advanced Tubo-Ovarian Cancers: Pooled Analysis of Individual Patient Data From the EORTC 55971 and CHORUS Trials
    Obstet. Gynecol. Surv., 74 (3), 156-158

Publications 2018

  1. González Martín A, Oza AM, Embleton AC, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Bertrand MA, Beale P, Cervantes A, Kent E, Kaplan RS, Parmar MKB, Scotto N, Perren TJ, ICON7 investigators (2018)
    Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer
    Gynecol Oncol, 152 (1), 53-60
    DOI 10.1016/j.ygyno.2018.08.036, PubMed 30449719
  2. Kleppe A, Albregtsen F, Vlatkovic L, Pradhan M, Nielsen B, Hveem TS, Askautrud HA, Kristensen GB, Nesbakken A, Trovik J, Wæhre H, Tomlinson I, Shepherd NA, Novelli M, Kerr DJ, Danielsen HE (2018)
    Chromatin organisation and cancer prognosis: a pan-cancer study
    Lancet Oncol, 19 (3), 356-369
    DOI 10.1016/S1470-2045(17)30899-9, PubMed 29402700
  3. Lindemann K (2018)
    Medical treatment of primary and recurrent cervical cancer
    Int. J. Gynecol. Cancer, 28 4, 29
  4. Lindemann K, Beale PJ, Rossi E, Goh JC, Vaughan MM, Tenney ME, Martyn JK, Sommeijer D, Iglesias JL, Kremmidiotis G, Simpson J, Doolin E, Lavranos TC, Leske A, Veillard AS, Espinoza D, Stockler MR, Rischin D, For ANZGOG and HCRN Collaborative Groups (2018)
    Phase I study of BNC105P, carboplatin and gemcitabine in partially platinum-sensitive ovarian cancer patients in first or second relapse (ANZGOG-1103)
    Cancer Chemother Pharmacol, 83 (1), 97-105
    DOI 10.1007/s00280-018-3706-5, PubMed 30368585
  5. Lindemann K, Gao B, Mapagu C, Fereday S, Emmanuel C, Alsop K, Traficante N, Australian Ovarian Cancer Study Group, Harnett PR, Bowtell DDL, deFazio A (2018)
    Response rates to second-line platinum-based therapy in ovarian cancer patients challenge the clinical definition of platinum resistance
    Gynecol Oncol, 150 (2), 239-246
    DOI 10.1016/j.ygyno.2018.05.020, PubMed 29807697
  6. Lindemann K, Zalewski K, Halaska MJ, Lindquist D (2018)
    Int. J. Gynecol. Cancer, 28 4, 2
  7. Lønning PE, Berge EO, Bjørnslett M, Minsaas L, Chrisanthar R, Høberg-Vetti H, Dulary C, Busato F, Bjørneklett S, Eriksen C, Kopperud R, Axcrona U, Davidson B, Bjørge L, Evans G, Howell A, Salvesen HB, Janszky I, Hveem K, Romundstad PR, Vatten LJ, Tost J, Dørum A, Knappskog S (2018)
    White Blood Cell BRCA1 Promoter Methylation Status and Ovarian Cancer Risk
    Ann Intern Med, 168 (5), 326-334
    DOI 10.7326/M17-0101, PubMed 29335712
  8. Nielsen B, Kleppe A, Hveem TS, Pradhan M, Syvertsen RA, Nesheim JA, Kristensen GB, Trovik J, Kerr DJ, Albregtsen F, Danielsen HE (2018)
    Association Between Proportion of Nuclei With High Chromatin Entropy and Prognosis in Gynecological Cancers
    J Natl Cancer Inst, 110 (12), 1400-1408
    DOI 10.1093/jnci/djy063, PubMed 29684152
  9. Noer MC, Leandersson P, Paulsen T, Rosthøj S, Antonsen SL, Borgfeldt C, Høgdall C (2018)
    Confounders other than comorbidity explain survival differences in Danish and Swedish ovarian cancer patients - a comparative cohort study
    Acta Oncol, 57 (8), 1100-1108
    DOI 10.1080/0284186X.2018.1440085, PubMed 29451070
  10. Simonsen TG, Lund KV, Hompland T, Kristensen GB, Rofstad EK (2018)
    DCE-MRI-Derived Measures of Tumor Hypoxia and Interstitial Fluid Pressure Predict Outcomes in Cervical Carcinoma
    Int J Radiat Oncol Biol Phys, 102 (4), 1193-1201
    DOI 10.1016/j.ijrobp.2018.04.035, PubMed 29859790
  11. Smogeli E, Cvancarova M, Wang Y, Davidson B, Kristensen G, Lindemann K (2018)
    Clinical Outcome of Patients With High-Risk Endometrial Carcinoma After Treatment With Chemotherapy Only
    Int J Gynecol Cancer, 28 (9), 1789-1795
    DOI 10.1097/IGC.0000000000001356, PubMed 30365455
  12. Solheim O, Skalleberg J, Warncke T, Ørstavik K, Tropé C, Fosså SD (2018)
    Long-term neurotoxicity and Raynaud's phenomenon in patients treated with cisplatin-based chemotherapy for malignant ovarian germ cell tumor
    Acta Obstet Gynecol Scand, 98 (2), 240-249
    DOI 10.1111/aogs.13477, PubMed 30289161
  13. Szczesny W, Langseth H, Myklebust TÅ, Kaern J, Tropé C, Paulsen T (2018)
    Survival after secondary cytoreductive surgery and chemotherapy compared with chemotherapy alone for first recurrence in patients with platinum-sensitive epithelial ovarian cancer and no residuals after primary treatment. A registry-based study
    Acta Obstet Gynecol Scand, 97 (8), 956-965
    DOI 10.1111/aogs.13361, PubMed 29790149

Publications 2017

  1. Andersson Y, Haavardtun SI, Davidson B, Dørum A, Fleten KG, Fodstad Ø, Flatmark K (2017)
    MOC31PE immunotoxin - targeting peritoneal metastasis from epithelial ovarian cancer
    Oncotarget, 8 (37), 61800-61809
    DOI 10.18632/oncotarget.18694, PubMed 28977905
  2. Davidson B, Hellesylt E, Holth A, Danielsen HE, Skeie-Jensen T, Katz B (2017)
    Neuron navigator-2 and cyclin D2 are new candidate prognostic markers in uterine sarcoma
    Virchows Arch, 471 (3), 355-362
    DOI 10.1007/s00428-017-2172-5, PubMed 28643014
  3. Eriksson AG, Beavis A, Soslow RA, Zhou Q, Abu-Rustum NR, Gardner GJ, Zivanovic O, Long Roche K, Sonoda Y, Leitao MM, Jewell EL (2017)
    A Comparison of the Detection of Sentinel Lymph Nodes Using Indocyanine Green and Near-Infrared Fluorescence Imaging Versus Blue Dye During Robotic Surgery in Uterine Cancer
    Int J Gynecol Cancer, 27 (4), 743-747
    DOI 10.1097/IGC.0000000000000959, PubMed 28375931
  4. Gansmo LB, Bjørnslett M, Halle MK, Salvesen HB, Romundstad P, Hveem K, Vatten L, Dørum A, Lønning PE, Knappskog S (2017)
    MDM2 promoter polymorphism del1518 (rs3730485) and its impact on endometrial and ovarian cancer risk
    BMC Cancer, 17 (1), 97
    DOI 10.1186/s12885-017-3094-y, PubMed 28158999
  5. Gutgold N, Davidson B, Catane LJ, Holth A, Hellesylt E, Tropé CG, Dørum A, Reich R (2017)
    TGFβ splicing and canonical pathway activation in high-grade serous carcinoma
    Virchows Arch, 470 (6), 665-678
    DOI 10.1007/s00428-017-2127-x, PubMed 28432432
  6. Hardell E, Josefson S, Ghaderi M, Skeie-Jensen T, Westbom-Fremer S, Cheek EH, Bell D, Selling J, Schoolmeester JK, Måsbäck A, Davidson B, Carlson JW (2017)
    Validation of a Mitotic Index Cutoff as a Prognostic Marker in Undifferentiated Uterine Sarcomas
    Am J Surg Pathol, 41 (9), 1231-1237
    DOI 10.1097/PAS.0000000000000894, PubMed 28622181
  7. Johansen N, Liavaag AH, Iversen OE, Dørum A, Braaten T, Michelsen TM (2017)
    Use of hormone replacement therapy after risk-reducing salpingo-oophorectomy
    Acta Obstet Gynecol Scand, 96 (5), 547-555
    DOI 10.1111/aogs.13120, PubMed 28236297
  8. Kildal W, Pradhan M, Cyll K, Jacobsen JE, Kristensen GB, Danielsen HE (2017)
    Characteristics of tumor cell DNA affect prognosis
    Tidsskr. Nor. Laegeforen., 137 (19), 1519-1523
  9. Kildal W, Pradhan M, Cyll K, Jacobsen JE, Kristensen GB, Danielsen HE (2017)
    [Properties of cancer cell DNA affects the prognosis]
    Tidsskr Nor Laegeforen, 137 (19)
    DOI 10.4045/tidsskr.16.0966, PubMed 29043733
  10. Landskron J, Kraggerud SM, Wik E, Dørum A, Bjørnslett M, Melum E, Helland Ø, Bjørge L, Lothe RA, Salvesen HB, Taskén K (2017)
    C77G in PTPRC (CD45) is no risk allele for ovarian cancer, but associated with less aggressive disease
    PLoS One, 12 (7), e0182030
    DOI 10.1371/journal.pone.0182030, PubMed 28759630
  11. Lindemann K, Gibbs E, Åvall-Lundqvist E, dePont Christensen R, Woie K, Kalling M, Auranen A, Grenman S, Hoegberg T, Rosenberg P, Skeie-Jensen T, Hjerpe E, Dørum A, Gebski V, Kristensen G (2017)
    Chemotherapy vs tamoxifen in platinum-resistant ovarian cancer: a phase III, randomised, multicentre trial (Ovaresist)
    Br J Cancer, 116 (4), 455-463
    DOI 10.1038/bjc.2016.435, PubMed 28118323
  12. Lindemann K, Kok PS, Stockler M, Jaaback K, Brand A (2017)
    Enhanced Recovery After Surgery for Advanced Ovarian Cancer: A Systematic Review of Interventions Trialed
    Int J Gynecol Cancer, 27 (6), 1274-1282
    DOI 10.1097/IGC.0000000000000981, PubMed 28498237
  13. Lindemann K, Kok PS, Stockler M, Sykes P, Brand A (2017)
    Enhanced Recovery After Surgery for Suspected Ovarian Malignancy: A Survey of Perioperative Practice Among Gynecologic Oncologists in Australia and New Zealand to Inform a Clinical Trial
    Int J Gynecol Cancer, 27 (5), 1046-1050
    DOI 10.1097/IGC.0000000000000982, PubMed 28525497
  14. Lund KV, Simonsen TG, Kristensen GB, Rofstad EK (2017)
    Pretreatment late-phase DCE-MRI predicts outcome in locally advanced cervix cancer
    Acta Oncol, 56 (5), 675-681
    DOI 10.1080/0284186X.2017.1294762, PubMed 28447564
  15. Meltzer-Gunnes CJ, Småstuen MC, Kristensen GB, Tropé CG, Lie AK, Vistad I (2017)
    Vulvar carcinoma in Norway: A 50-year perspective on trends in incidence, treatment and survival
    Gynecol Oncol, 145 (3), 543-548
    DOI 10.1016/j.ygyno.2017.03.008, PubMed 28356187
  16. Minig L, Heitz F, Cibula D, Bakkum-Gamez JN, Germanova A, Dowdy SC, Kalogera E, Zapardiel I, Lindemann K, Harter P, Scambia G, Petrillo M, Zorrero C, Zanagnolo V, Rebollo JMC, du Bois A, Fotopoulou C (2017)
    Patterns of Lymph Node Metastases in Apparent Stage I Low-Grade Epithelial Ovarian Cancer: A Multicenter Study
    Ann Surg Oncol, 24 (9), 2720-2726
    DOI 10.1245/s10434-017-5919-y, PubMed 28608122
  17. Ray-Coquard I, Trama A, Seckl MJ, Fotopoulou C, Pautier P, Pignata S, Kristensen G, Mangili G, Falconer H, Massuger L, Sehouli J, Pujade-Lauraine E, Lorusso D, Amant F, Rokkones E, Vergote I, Ledermann JA, RARECARENet Working Group (2017)
    Rare ovarian tumours: Epidemiology, treatment challenges in and outside a network setting
    Eur J Surg Oncol, 45 (1), 67-74
    DOI 10.1016/j.ejso.2017.09.025, PubMed 29108961
  18. Skalleberg J, Solheim O, Fosså SD, Småstuen MC, Osnes T, Gundersen POM, Bunne M (2017)
    Long-term ototoxicity in women after cisplatin treatment for ovarian germ cell cancer
    Gynecol Oncol, 145 (1), 148-153
    DOI 10.1016/j.ygyno.2017.02.006, PubMed 28202195
  19. Solheim O, Førsund M, Tropé CG, Kraggerud SM, Nesland JM, Davidson B (2017)
    Epithelial-mesenchymal transition markers in malignant ovarian germ cell tumors
    APMIS, 125 (9), 781-786
    DOI 10.1111/apm.12715, PubMed 28585395
  20. Steen R, Dahl AA, Hess SL, Kiserud CE (2017)
    A study of chronic fatigue in Norwegian cervical cancer survivors
    Gynecol Oncol, 146 (3), 630-635
    DOI 10.1016/j.ygyno.2017.05.028, PubMed 28552254
  21. Vistad I, Bjørge L, Solheim O, Fiane B, Sachse K, Tjugum J, Skrøppa S, Bentzen AG, Stokstad T, Iversen GA, Salvesen HB, Kristensen GB, Dørum A (2017)
    A national, prospective observational study of first recurrence after primary treatment for gynecological cancer in Norway
    Acta Obstet Gynecol Scand, 96 (10), 1162-1169
    DOI 10.1111/aogs.13199, PubMed 28795770
  22. Wiedmann MKH, Brunborg C, Di Ieva A, Lindemann K, Johannesen TB, Vatten L, Helseth E, Zwart JA (2017)
    The impact of body mass index and height on the risk for glioblastoma and other glioma subgroups: a large prospective cohort study
    Neuro Oncol, 19 (7), 976-985
    DOI 10.1093/neuonc/now272, PubMed 28040713
  23. Wiedmann MKH, Brunborg C, Di Ieva A, Lindemann K, Johannesen TB, Vatten L, Helseth E, Zwart JA (2017)
    Overweight, obesity and height as risk factors for meningioma, glioma, pituitary adenoma and nerve sheath tumor: a large population-based prospective cohort study
    Acta Oncol, 56 (10), 1302-1309
    DOI 10.1080/0284186X.2017.1330554, PubMed 28548875
  24. Zalewski K, Lindemann K, Halaska MJ, Zapardiel I, Laky R, Chereau E, Lindquist D, Polterauer S, Sukhin V, Dursun P (2017)
    A Call for New Communication Channels for Gynecological Oncology Trainees: A Survey on Social Media Use and Educational Needs by the European Network of Young Gynecological Oncologists
    Int J Gynecol Cancer, 27 (3), 620-626
    DOI 10.1097/IGC.0000000000000917, PubMed 28187096

Publications 2016

  1. Bjørge T, Skare GB, Bjørge L, Tropé A, Lönnberg S (2016)
    Adverse Pregnancy Outcomes After Treatment for Cervical Intraepithelial Neoplasia
    Obstet Gynecol, 128 (6), 1265-1273
    DOI 10.1097/AOG.0000000000001777, PubMed 27824756
  2. Davidson B, Kjæreng ML, Førsund M, Danielsen HE, Kristensen GB, Abeler VM (2016)
    Progesterone Receptor Expression Is an Independent Prognosticator in FIGO Stage I Uterine Leiomyosarcoma
    Am J Clin Pathol, 145 (4), 449-58
    DOI 10.1093/ajcp/aqw030, PubMed 27149024
  3. Fjeldbo CS, Julin CH, Lando M, Forsberg MF, Aarnes EK, Alsner J, Kristensen GB, Malinen E, Lyng H (2016)
    Integrative Analysis of DCE-MRI and Gene Expression Profiles in Construction of a Gene Classifier for Assessment of Hypoxia-Related Risk of Chemoradiotherapy Failure in Cervical Cancer
    Clin Cancer Res, 22 (16), 4067-76
    DOI 10.1158/1078-0432.CCR-15-2322, PubMed 27012812
  4. Fjeldbo CS, Aarnes EK, Malinen E, Kristensen GB, Lyng H (2016)
    Identification and Validation of Reference Genes for RT-qPCR Studies of Hypoxia in Squamous Cervical Cancer Patients
    PLoS One, 11 (5), e0156259
    DOI 10.1371/journal.pone.0156259, PubMed 27244197
  5. Gansmo LB, Bjørnslett M, Halle MK, Salvesen HB, Dørum A, Birkeland E, Hveem K, Romundstad P, Vatten L, Lønning PE, Knappskog S (2016)
    The MDM4 SNP34091 (rs4245739) C-allele is associated with increased risk of ovarian-but not endometrial cancer
    Tumour Biol, 37 (8), 10697-702
    DOI 10.1007/s13277-016-4940-2, PubMed 26867771
  6. Gao B, Lindemann K, Anderson L, Fereday S, Hung J, Alsop K, Tothill RW, Gebski V, Kennedy C, Balleine RL, Australian Ovarian Cancer Study Group, Harnett PR, Bowtell DD, DeFazio A (2016)
    Serous ovarian and primary peritoneal cancers: A comparative analysis of clinico-pathological features, molecular subtypes and treatment outcome
    Gynecol Oncol, 142 (3), 458-64
    DOI 10.1016/j.ygyno.2016.06.023, PubMed 27444035
  7. Grabowski JP, Harter P, Heitz F, Pujade-Lauraine E, Reuss A, Kristensen G, Ray-Coquard I, Heitz J, Traut A, Pfisterer J, du Bois A (2016)
    Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase
    Gynecol Oncol, 140 (3), 457-62
    DOI 10.1016/j.ygyno.2016.01.022, PubMed 26807488
  8. Horwitz V, Davidson B, Stern D, Tropé CG, Tavor Re'em T, Reich R (2016)
    Ezrin Is Associated with Disease Progression in Ovarian Carcinoma
    PLoS One, 11 (9), e0162502
    DOI 10.1371/journal.pone.0162502, PubMed 27622508
  9. Lindemann K (2016)
    Medical treatment of primary or recurrent cervical cancer
    Int. J. Gynecol. Cancer, 26 1, 42-43
  10. Lindemann K, Halaska MJ, Zalewski K (2016)
    Surgical treatment of primary ovarian fallopian tube and peritoneal cancer
    Int. J. Gynecol. Cancer, 26 1, 5-8
  11. Lindemann K, Kristensen G, Mirza MR, Davies L, Hilpert F, Romero I, Ayhan A, Burges A, Rubio MJ, Raspagliesi F, Huizing M, Creemers GJ, Lykka M, Lee CK, Gebski V, Pujade-Lauraine E (2016)
    Poor concordance between CA-125 and RECIST at the time of disease progression in patients with platinum-resistant ovarian cancer: analysis of the AURELIA trial
    Ann Oncol, 27 (8), 1505-10
    DOI 10.1093/annonc/mdw238, PubMed 27407100
  12. Lindemann K, Zalewski K, Halaska MJ, LiFE Team (2016)
    Int. J. Gynecol. Cancer, 26 1, 2
  13. Lindemann K, Zalewski K, Halaska MJ, Lindquist D, The LiFE Team (2016)
    Life - Literature for ENYGO
    Int. J. Gynecol. Cancer, 26 4, 2-73
  14. Lönnberg S, Andreassen T, Engesæter B, Lilleng R, Kleven C, Skare A, Johansson K, Fredheim CS, Tropé A (2016)
    Impact of scheduled appointments on cervical screening participation in Norway: a randomised intervention
    BMJ Open, 6 (11), e013728
    DOI 10.1136/bmjopen-2016-013728, PubMed 28186949
  15. Makar AP, Tropé CG, Tummers P, Denys H, Vandecasteele K (2016)
    Advanced Ovarian Cancer: Primary or Interval Debulking? Five Categories of Patients in View of the Results of Randomized Trials and Tumor Biology: Primary Debulking Surgery and Interval Debulking Surgery for Advanced Ovarian Cancer
    Oncologist, 21 (6), 745-54
    DOI 10.1634/theoncologist.2015-0239, PubMed 27009938
  16. Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, Fabbro M, Ledermann JA, Lorusso D, Vergote I, Ben-Baruch NE, Marth C, Mądry R, Christensen RD, Berek JS, Dørum A, Tinker AV, du Bois A, González-Martín A, Follana P, Benigno B, Rosenberg P, Gilbert L, Rimel BJ, Buscema J et al. (2016)
    Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
    N Engl J Med, 375 (22), 2154-2164
    DOI 10.1056/NEJMoa1611310, PubMed 27717299
  17. Nymoen DA, Slipicevic A, Holth A, Emilsen E, Hetland Falkenthal TE, Tropé CG, Reich R, Flørenes VA, Davidson B (2016)
    MiR-29a is a candidate biomarker of better survival in metastatic high-grade serous carcinoma
    Hum Pathol, 54, 74-81
    DOI 10.1016/j.humpath.2016.03.010, PubMed 27063471
  18. Sert BM, Boggess JF, Ahmad S, Jackson AL, Stavitzski NM, Dahl AA, Holloway RW (2016)
    Robot-assisted versus open radical hysterectomy: A multi-institutional experience for early-stage cervical cancer
    Eur J Surg Oncol, 42 (4), 513-22
    DOI 10.1016/j.ejso.2015.12.014, PubMed 26843445
  19. Smogeli E, Davidson B, Cvancarova M, Holth A, Katz B, Risberg B, Kristensen G, Lindemann K (2016)
    L1CAM as a prognostic marker in stage I endometrial cancer: a validation study
    BMC Cancer, 16, 596
    DOI 10.1186/s12885-016-2631-4, PubMed 27488577
  20. Sorio R, Roemer-Becuwe C, Hilpert F, Gibbs E, García Y, Kaern J, Huizing M, Witteveen P, Zagouri F, Coeffic D, Lück HJ, González-Martín A, Kristensen G, Levaché CB, Lee CK, Gebski V, Pujade-Lauraine E, AURELIA Investigators (2016)
    Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial
    Gynecol Oncol, 144 (1), 65-71
    DOI 10.1016/j.ygyno.2016.11.006, PubMed 27871723
  21. Szczesny W, Vistad I, Kaern J, Nakling J, Tropé C, Paulsen T (2016)
    Impact of hospital type and treatment on long-term survival among patients with FIGO Stage IIIC epithelial ovarian cancer: follow-up through two recurrences and three treatment lines in search for predictors for survival
    Eur J Gynaecol Oncol, 37 (3), 305-11
    DOI 10.12892/ejgo3007.2016, PubMed 27352555
  22. Tambe M, Pruikkonen S, Mäki-Jouppila J, Chen P, Elgaaen BV, Straume AH, Huhtinen K, Cárpen O, Lønning PE, Davidson B, Hautaniemi S, Kallio MJ (2016)
    Novel Mad2-targeting miR-493-3p controls mitotic fidelity and cancer cells' sensitivity to paclitaxel
    Oncotarget, 7 (11), 12267-85
    DOI 10.18632/oncotarget.7860, PubMed 26943585
  23. Trillsch F, Mahner S, Hilpert F, Davies L, García-Martínez E, Kristensen G, Savarese A, Vuylsteke P, Los M, Zagouri F, Gladieff L, Sehouli J, Khoon Lee C, Gebski V, Pujade-Lauraine E (2016)
    Prognostic and predictive effects of primary versus secondary platinum resistance for bevacizumab treatment for platinum-resistant ovarian cancer in the AURELIA trial
    Ann Oncol, 27 (9), 1733-9
    DOI 10.1093/annonc/mdw236, PubMed 27287207
  24. Zalewski K, Lindemann K, Halaska MJ (2016)
    Medical treatment of primary ovarian cancer
    Int. J. Gynecol. Cancer, 26 1, 9-11
  25. Zhou C, Clamp A, Backen A, Berzuini C, Renehan A, Banks RE, Kaplan R, Scherer SJ, Kristensen GB, Pujade-Lauraine E, Dive C, Jayson GC (2016)
    Systematic analysis of circulating soluble angiogenesis-associated proteins in ICON7 identifies Tie2 as a biomarker of vascular progression on bevacizumab
    Br J Cancer, 115 (2), 228-35
    DOI 10.1038/bjc.2016.194, PubMed 27351218

Publications 2015

  1. Bartlett TE, Jones A, Goode EL, Fridley BL, Cunningham JM, Berns EM, Wik E, Salvesen HB, Davidson B, Trope CG, Lambrechts S, Vergote I, Widschwendter M (2015)
    Intra-Gene DNA Methylation Variability Is a Clinically Independent Prognostic Marker in Women's Cancers
    PLoS One, 10 (12), e0143178
    DOI 10.1371/journal.pone.0143178, PubMed 26629914
  2. Bjørnslett M, Dahl AA, Sørebø Ø, Dørum A (2015)
    Psychological distress related to BRCA testing in ovarian cancer patients
    Fam Cancer, 14 (4), 495-504
    DOI 10.1007/s10689-015-9811-2, PubMed 25980896
  3. Davidson B, Holth A, Hellesylt E, Hadar R, Katz B, Tropé CG, Reich R (2015)
    HUR mRNA expression in ovarian high-grade serous carcinoma effusions is associated with poor survival
    Hum Pathol, 48, 95-101
    DOI 10.1016/j.humpath.2015.09.027, PubMed 26640230
  4. du Bois A, Kristensen G, Ray-Coquard I, Reuss A, Pignata S, Colombo N, Denison U, Vergote I, Del Campo JM, Ottevanger P, Heubner M, Minarik T, Sevin E, de Gregorio N, Bidziński M, Pfisterer J, Malander S, Hilpert F, Mirza MR, Scambia G, Meier W, Nicoletto MO, Bjørge L, Lortholary A, Sailer MO et al. (2015)
    Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial
    Lancet Oncol, 17 (1), 78-89
    DOI 10.1016/S1470-2045(15)00366-6, PubMed 26590673
  5. Katz B, Tropé CG, Reich R, Davidson B (2015)
    MicroRNAs in Ovarian Cancer
    Hum Pathol, 46 (9), 1245-56
    DOI 10.1016/j.humpath.2015.06.013, PubMed 26216350
  6. Lando M, Fjeldbo CS, Wilting SM, C Snoek B, Aarnes EK, Forsberg MF, Kristensen GB, Steenbergen RD, Lyng H (2015)
    Interplay between promoter methylation and chromosomal loss in gene silencing at 3p11-p14 in cervical cancer
    Epigenetics, 10 (10), 970-80
    DOI 10.1080/15592294.2015.1085140, PubMed 26291246
  7. Lindemann K, Cvancarova M, Eskild A (2015)
    Body mass index, diabetes and survival after diagnosis of endometrial cancer: A report from the HUNT-Survey
    Gynecol Oncol, 139 (3), 476-80
    DOI 10.1016/j.ygyno.2015.09.088, PubMed 26434365
  8. Murbraech K, Solheim O, Aulie HM, Fossa SD, Aakhus S (2015)
    The impact of cisplatinum-based chemotherapy on ventricular function and cardiovascular risk factors in female survivors after malignant germ cell cancer
    ESC Heart Fail, 2 (3), 142-149
    DOI 10.1002/ehf2.12048, PubMed 28834675
  9. Nymoen DA, Hetland Falkenthal TE, Holth A, Ow GS, Ivshina AV, Tropé CG, Kuznetsov VA, Staff AC, Davidson B (2015)
    Expression and clinical role of chemoresponse-associated genes in ovarian serous carcinoma
    Gynecol Oncol, 139 (1), 30-9
    DOI 10.1016/j.ygyno.2015.07.107, PubMed 26232338
  10. Nymoen DA, Holth A, Hetland Falkenthal TE, Tropé CG, Davidson B (2015)
    CIAPIN1 and ABCA13 are markers of poor survival in metastatic ovarian serous carcinoma
    Mol Cancer, 14, 44
    DOI 10.1186/s12943-015-0317-1, PubMed 25889687
  11. Oza AM, Cook AD, Pfisterer J, Embleton A, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Park-Simon TW, Rustin G, Joly F, Mirza MR, Plante M, Quinn M, Poveda A, Jayson GC, Stark D, Swart AM, Farrelly L, Kaplan R, Parmar MK, Perren TJ, ICON7 trial investigators (2015)
    Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial
    Lancet Oncol, 16 (8), 928-36
    DOI 10.1016/S1470-2045(15)00086-8, PubMed 26115797
  12. Ruhlmann CH, Iversen TZ, Okera M, Muhic A, Kristensen G, Feyer P, Hansen O, Herrstedt J (2015)
    Multinational study exploring patients' perceptions of side-effects induced by chemo-radiotherapy
    Radiother Oncol, 117 (2), 333-7
    DOI 10.1016/j.radonc.2015.09.014, PubMed 26372344
  13. Sehouli J, Fotopoulou C, Erol E, Richter R, Reuss A, Mahner S, Lauraine EP, Kristensen G, Herrstedt J, du Bois A, Pfisterer J (2015)
    Alopecia as surrogate marker for chemotherapy response in patients with primary epithelial ovarian cancer: a metaanalysis of four prospective randomised phase III trials with 5114 patients
    Eur J Cancer, 51 (7), 825-32
    DOI 10.1016/j.ejca.2015.01.008, PubMed 25771433
  14. Teschendorff AE, Lee SH, Jones A, Fiegl H, Kalwa M, Wagner W, Chindera K, Evans I, Dubeau L, Orjalo A, Horlings HM, Niederreiter L, Kaser A, Yang W, Goode EL, Fridley BL, Jenner RG, Berns EM, Wik E, Salvesen HB, Wisman GB, van der Zee AG, Davidson B, Trope CG, Lambrechts S et al. (2015)
    HOTAIR and its surrogate DNA methylation signature indicate carboplatin resistance in ovarian cancer
    Genome Med, 7, 108
    DOI 10.1186/s13073-015-0233-4, PubMed 26497652
  15. Wiedmann M, Brunborg C, Lindemann K, Johannesen TB, Vatten L, Helseth E, Zwart JA (2015)
    Smoking, obesity and the risk of pituitary adenoma: a large prospective cohort study (The HUNT Study)
    Eur J Epidemiol, 31 (1), 95-8
    DOI 10.1007/s10654-015-0033-6, PubMed 25903163

Publications 2014

  1. Amant F, Floquet A, Friedlander M, Kristensen G, Mahner S, Nam EJ, Powell MA, Ray-Coquard I, Siddiqui N, Sykes P, Westermann AM, Seddon B (2014)
    Gynecologic Cancer InterGroup (GCIG) consensus review for endometrial stromal sarcoma
    Int J Gynecol Cancer, 24 (9 Suppl 3), S67-72
    DOI 10.1097/IGC.0000000000000205, PubMed 25033257
  2. Davidson B, Holth A, Hellesylt E, Tan TZ, Huang RY, Tropé C, Nesland JM, Thiery JP (2014)
    The clinical role of epithelial-mesenchymal transition and stem cell markers in advanced-stage ovarian serous carcinoma effusions
    Hum Pathol, 46 (1), 1-8
    DOI 10.1016/j.humpath.2014.10.004, PubMed 25455994
  3. Davidson B, Nymoen DA, Elgaaen BV, Staff AC, Tropé CG, Kærn J, Reich R, Falkenthal TE (2014)
    BUB1 mRNA is significantly co-expressed with AURKA and AURKB mRNA in advanced-stage ovarian serous carcinoma
    Virchows Arch, 464 (6), 701-7
    DOI 10.1007/s00428-014-1577-7, PubMed 24756216
  4. Davidson B, Rosenfeld YB, Holth A, Hellesylt E, Tropé CG, Reich R, Yisraeli JK (2014)
    VICKZ2 protein expression in ovarian serous carcinoma effusions is associated with poor survival
    Hum Pathol, 45 (7), 1520-8
    DOI 10.1016/j.humpath.2014.03.005, PubMed 24814803
  5. Davidson B, Trope CG, Reich R (2014)
    The role of the tumor stroma in ovarian cancer
    Front Oncol, 4, 104
    DOI 10.3389/fonc.2014.00104, PubMed 24860785
  6. Davidson B, Tropé CG, Reich R (2014)
    The clinical and diagnostic role of microRNAs in ovarian carcinoma
    Gynecol Oncol, 133 (3), 640-6
    DOI 10.1016/j.ygyno.2014.03.575, PubMed 24713546
  7. Friedlander ML, Covens A, Glasspool RM, Hilpert F, Kristensen G, Kwon S, Selle F, Small W, Witteveen E, Russell P (2014)
    Gynecologic Cancer InterGroup (GCIG) consensus review for mullerian adenosarcoma of the female genital tract
    Int J Gynecol Cancer, 24 (9 Suppl 3), S78-82
    DOI 10.1097/IGC.0000000000000239, PubMed 25341585
  8. Hompland T, Lund KV, Ellingsen C, Kristensen GB, Rofstad EK (2014)
    Peritumoral interstitial fluid flow velocity predicts survival in cervical carcinoma
    Radiother Oncol, 113 (1), 132-8
    DOI 10.1016/j.radonc.2014.09.011, PubMed 25443501
  9. Huang R, Wu D, Yuan Y, Li X, Holm R, Trope CG, Nesland JM, Suo Z (2014)
    CD117 expression in fibroblasts-like stromal cells indicates unfavorable clinical outcomes in ovarian carcinoma patients
    PLoS One, 9 (11), e112209
    DOI 10.1371/journal.pone.0112209, PubMed 25380303
  10. Lindemann K, Malander S, Christensen RD, Mirza MR, Kristensen GB, Aavall-Lundqvist E, Vergote I, Rosenberg P, Boman K, Nordstrøm B (2014)
    Examestane in advanced or recurrent endometrial carcinoma: a prospective phase II study by the Nordic Society of Gynecologic Oncology (NSGO)
    BMC Cancer, 14, 68
    DOI 10.1186/1471-2407-14-68, PubMed 24498853
  11. Micci F, Haugom L, Abeler VM, Davidson B, Tropé CG, Heim S (2014)
    Genomic profile of ovarian carcinomas
    BMC Cancer, 14, 315
    DOI 10.1186/1471-2407-14-315, PubMed 24886194
  12. Micci F, Panagopoulos I, Thorsen J, Davidson B, Tropé CG, Heim S (2014)
    Low frequency of ESRRA-C11orf20 fusion gene in ovarian carcinomas
    PLoS Biol, 12 (2), e1001784
    DOI 10.1371/journal.pbio.1001784, PubMed 24504521
  13. Nielsen B, Hveem TS, Kildal W, Abeler VM, Kristensen GB, Albregtsen F, Danielsen HE (2014)
    Entropy-based adaptive nuclear texture features are independent prognostic markers in a total population of uterine sarcomas
    Cytometry A, 87 (4), 315-25
    DOI 10.1002/cyto.a.22601, PubMed 25483227
  14. Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, Sorio R, Vergote I, Witteveen P, Bamias A, Pereira D, Wimberger P, Oaknin A, Mirza MR, Follana P, Bollag D, Ray-Coquard I (2014)
    Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial
    J Clin Oncol, 32 (13), 1302-8
    DOI 10.1200/JCO.2013.51.4489, PubMed 24637997
  15. Sagae S, Susumu N, Viswanathan AN, Aoki D, Backes FJ, Provencher DM, Vaughan M, Creutzberg CL, Kurzeder C, Kristensen G, Lee C, Kurtz JE, Glasspool RM, Small W (2014)
    Gynecologic Cancer InterGroup (GCIG) consensus review for uterine serous carcinoma
    Int J Gynecol Cancer, 24 (9 Suppl 3), S83-9
    DOI 10.1097/IGC.0000000000000264, PubMed 25341586
  16. Slipicevic A, Holth A, Hellesylt E, Tropé CG, Davidson B, Flørenes VA (2014)
    Wee1 is a novel independent prognostic marker of poor survival in post-chemotherapy ovarian carcinoma effusions
    Gynecol Oncol, 135 (1), 118-24
    DOI 10.1016/j.ygyno.2014.07.102, PubMed 25093290
  17. Smebye ML, Sveen A, Haugom L, Davidson B, Tropé CG, Lothe RA, Heim S, Skotheim RI, Micci F (2014)
    Chromosome 19 rearrangements in ovarian carcinomas: zinc finger genes are particularly targeted
    Genes Chromosomes Cancer, 53 (7), 558-67
    DOI 10.1002/gcc.22166, PubMed 24634323
  18. Solheim O, Gershenson DM, Tropé CG, Rokkones E, Sun CC, Weedon-Fekjaer H, Fosså SD (2014)
    Prognostic factors in malignant ovarian germ cell tumours (The Surveillance, Epidemiology and End Results experience 1978-2010)
    Eur J Cancer, 50 (11), 1942-50
    DOI 10.1016/j.ejca.2014.03.288, PubMed 24857045
  19. Solheim O, Tropé CG, Rokkones E, Kærn J, Paulsen T, Salvesen HB, Hagen B, Vereide AB, Fosså SD (2014)
    Fertility and gonadal function after adjuvant therapy in women diagnosed with a malignant ovarian germ cell tumor (MOGCT) during the "cisplatin era"
    Gynecol Oncol, 136 (2), 224-9
    DOI 10.1016/j.ygyno.2014.12.010, PubMed 25511159
  20. Tuft Stavnes H, Nymoen DA, Hetland Falkenthal TE, Kærn J, Tropé CG, Davidson B (2014)
    APOA1 mRNA expression in ovarian serous carcinoma effusions is a marker of longer survival
    Am J Clin Pathol, 142 (1), 51-7
    DOI 10.1309/AJCPD8NBSHXRXQL7, PubMed 24926085
  21. Vaksman O, Tropé C, Davidson B, Reich R (2014)
    Exosome-derived miRNAs and ovarian carcinoma progression
    Carcinogenesis, 35 (9), 2113-20
    DOI 10.1093/carcin/bgu130, PubMed 24925027
  22. Vilming Elgaaen B, Olstad OK, Haug KB, Brusletto B, Sandvik L, Staff AC, Gautvik KM, Davidson B (2014)
    Global miRNA expression analysis of serous and clear cell ovarian carcinomas identifies differentially expressed miRNAs including miR-200c-3p as a prognostic marker
    BMC Cancer, 14, 80
    DOI 10.1186/1471-2407-14-80, PubMed 24512620
  23. Wang Y, Herrstedt J, Havsteen H, DePoint Christensen R, Mirza MR, Lund B, Maenpaa J, Kristensen G (2014)
    A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer
    BMC Cancer, 14, 937
    DOI 10.1186/1471-2407-14-937, PubMed 25494701

Publications 2013

  1. Andersen EK, Hole KH, Lund KV, Sundfør K, Kristensen GB, Lyng H, Malinen E (2013)
    Pharmacokinetic parameters derived from dynamic contrast enhanced MRI of cervical cancers predict chemoradiotherapy outcome
    Radiother Oncol, 107 (1), 117-22
    DOI 10.1016/j.radonc.2012.11.007, PubMed 23333024
  2. Baumbusch LO, Helland Å, Wang Y, Liestøl K, Schaner ME, Holm R, Etemadmoghadam D, Alsop K, Brown P, Australian Ovarian Cancer Study Group, Mitchell G, Fereday S, DeFazio A, Bowtell DD, Kristensen GB, Lingjærde OC, Børresen-Dale AL (2013)
    High levels of genomic aberrations in serous ovarian cancers are associated with better survival
    PLoS One, 8 (1), e54356
    DOI 10.1371/journal.pone.0054356, PubMed 23372714
  3. Davidson B, Abeler VM, Førsund M, Holth A, Yang Y, Kobayashi Y, Chen L, Kristensen GB, Shih IeM, Wang TL (2013)
    Gene expression signatures of primary and metastatic uterine leiomyosarcoma
    Hum Pathol, 45 (4), 691-700
    DOI 10.1016/j.humpath.2013.11.003, PubMed 24485798
  4. Davidson B, Smith Y, Nesland JM, Kærn J, Reich R, Tropè CG (2013)
    Defining a prognostic marker panel for patients with ovarian serous carcinoma effusion
    Hum Pathol, 44 (11), 2449-60
    DOI 10.1016/j.humpath.2013.06.003, PubMed 24011953
  5. Greimel E, Kristensen GB, van der Burg ME, Coronado P, Rustin G, del Rio AS, Reed NS, Nordal RR, Coens C, Vergote I, European Organization for Research and Treatment of Cancer - Gynaecological Cancer Group and NCIC Clinical Trials Group (2013)
    Quality of life of advanced ovarian cancer patients in the randomized phase III study comparing primary debulking surgery versus neo-adjuvant chemotherapy
    Gynecol Oncol, 131 (2), 437-44
    DOI 10.1016/j.ygyno.2013.08.014, PubMed 23994107
  6. Lando M, Wilting SM, Snipstad K, Clancy T, Bierkens M, Aarnes EK, Holden M, Stokke T, Sundfør K, Holm R, Kristensen GB, Steenbergen RD, Lyng H (2013)
    Identification of eight candidate target genes of the recurrent 3p12-p14 loss in cervical cancer by integrative genomic profiling
    J Pathol, 230 (1), 59-69
    DOI 10.1002/path.4168, PubMed 23335387
  7. Onsrud M, Cvancarova M, Hellebust TP, Tropé CG, Kristensen GB, Lindemann K (2013)
    Long-term outcomes after pelvic radiation for early-stage endometrial cancer
    J Clin Oncol, 31 (31), 3951-6
    DOI 10.1200/JCO.2013.48.8023, PubMed 24019546
  8. Solheim O, Kærn J, Tropé CG, Rokkones E, Dahl AA, Nesland JM, Fosså SD (2013)
    Malignant ovarian germ cell tumors: presentation, survival and second cancer in a population based Norwegian cohort (1953-2009)
    Gynecol Oncol, 131 (2), 330-5
    DOI 10.1016/j.ygyno.2013.08.028, PubMed 24001518
  9. Stark D, Nankivell M, Pujade-Lauraine E, Kristensen G, Elit L, Stockler M, Hilpert F, Cervantes A, Brown J, Lanceley A, Velikova G, Sabate E, Pfisterer J, Carey MS, Beale P, Qian W, Swart AM, Oza A, Perren T (2013)
    Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial
    Lancet Oncol, 14 (3), 236-43
    DOI 10.1016/S1470-2045(12)70567-3, PubMed 23333117
  10. Stavnes HT, Holth A, Don T, Kærn J, Vaksman O, Reich R, Trope' CG, Davidson B (2013)
    HOXB8 expression in ovarian serous carcinoma effusions is associated with shorter survival
    Gynecol Oncol, 129 (2), 358-63
    DOI 10.1016/j.ygyno.2013.02.021, PubMed 23438671
  11. Vaksman O, Davidson B, Tropé C, Reich R (2013)
    Calreticulin expression is reduced in high-grade ovarian serous carcinoma effusions compared with primary tumors and solid metastases
    Hum Pathol, 44 (12), 2677-83
    DOI 10.1016/j.humpath.2013.07.009, PubMed 24060004
  12. Vettukattil R, Hetland TE, Flørenes VA, Kærn J, Davidson B, Bathen TF (2013)
    Proton magnetic resonance metabolomic characterization of ovarian serous carcinoma effusions: chemotherapy-related effects and comparison with malignant mesothelioma and breast carcinoma
    Hum Pathol, 44 (9), 1859-66
    DOI 10.1016/j.humpath.2013.02.009, PubMed 23656974

Publications 2012

  1. Bjørnslett M, Knappskog S, Lønning PE, Dørum A (2012)
    Effect of the MDM2 promoter polymorphisms SNP309T>G and SNP285G>C on the risk of ovarian cancer in BRCA1 mutation carriers
    BMC Cancer, 12, 454
    DOI 10.1186/1471-2407-12-454, PubMed 23039163
  2. Brusegard K, Stavnes HT, Nymoen DA, Flatmark K, Trope CG, Davidson B (2012)
    Rab25 is overexpressed in Müllerian serous carcinoma compared to malignant mesothelioma
    Virchows Arch, 460 (2), 193-202
    DOI 10.1007/s00428-011-1191-x, PubMed 22249560
  3. Davidson B, Abeler VM, Hellesylt E, Holth A, Shih IeM, Skeie-Jensen T, Chen L, Yang Y, Wang TL (2012)
    Gene expression signatures differentiate uterine endometrial stromal sarcoma from leiomyosarcoma
    Gynecol Oncol, 128 (2), 349-55
    DOI 10.1016/j.ygyno.2012.11.021, PubMed 23178314
  4. Davidson B, Holth A, Nguyen MT, Tropé CG, Wu C (2012)
    Migfilin, α-parvin and β-parvin are differentially expressed in ovarian serous carcinoma effusions, primary tumors and solid metastases
    Gynecol Oncol, 128 (2), 364-70
    DOI 10.1016/j.ygyno.2012.10.015, PubMed 23099104
  5. Elgaaen BV, Olstad OK, Sandvik L, Odegaard E, Sauer T, Staff AC, Gautvik KM (2012)
    ZNF385B and VEGFA are strongly differentially expressed in serous ovarian carcinomas and correlate with survival
    PLoS One, 7 (9), e46317
    DOI 10.1371/journal.pone.0046317, PubMed 23029477
  6. Elstrand MB, Sandstad B, Oksefjell H, Davidson B, Tropé CG (2012)
    Prognostic significance of residual tumor in patients with epithelial ovarian carcinoma stage IV in a 20 year perspective
    Acta Obstet Gynecol Scand, 91 (3), 308-17
    DOI 10.1111/j.1600-0412.2011.01316.x, PubMed 22050605
  7. Fotopoulou C, Zang R, Gultekin M, Cibula D, Ayhan A, Liu D, Richter R, Braicu I, Mahner S, Harter P, Trillsch F, Kumar S, Peiretti M, Dowdy SC, Maggioni A, Trope C, Sehouli J (2012)
    Value of tertiary cytoreductive surgery in epithelial ovarian cancer: an international multicenter evaluation
    Ann Surg Oncol, 20 (4), 1348-54
    DOI 10.1245/s10434-012-2673-z, PubMed 23054114
  8. Gillet JP, Calcagno AM, Varma S, Davidson B, Bunkholt Elstrand M, Ganapathi R, Kamat AA, Sood AK, Ambudkar SV, Seiden MV, Rueda BR, Gottesman MM (2012)
    Multidrug resistance-linked gene signature predicts overall survival of patients with primary ovarian serous carcinoma
    Clin Cancer Res, 18 (11), 3197-206
    DOI 10.1158/1078-0432.CCR-12-0056, PubMed 22492981
  9. Halle C, Andersen E, Lando M, Aarnes EK, Hasvold G, Holden M, Syljuåsen RG, Sundfør K, Kristensen GB, Holm R, Malinen E, Lyng H (2012)
    Hypoxia-induced gene expression in chemoradioresistant cervical cancer revealed by dynamic contrast-enhanced MRI
    Cancer Res, 72 (20), 5285-95
    DOI 10.1158/0008-5472.CAN-12-1085, PubMed 22890239
  10. Hetland TE, Holth A, Kærn J, Flørenes VA, Tropé CG, Davidson B (2012)
    HMGA2 protein expression in ovarian serous carcinoma effusions, primary tumors, and solid metastases
    Virchows Arch, 460 (5), 505-13
    DOI 10.1007/s00428-012-1228-9, PubMed 22476403
  11. Hetland TE, Kærn J, Skrede M, Sandstad B, Tropé C, Davidson B, Flørenes VA (2012)
    Predicting platinum resistance in primary advanced ovarian cancer patients with an in vitro resistance index
    Cancer Chemother Pharmacol, 69 (5), 1307-14
    DOI 10.1007/s00280-012-1835-9, PubMed 22302409
  12. Hetland TE, Nymoen DA, Emilsen E, Kærn J, Tropé CG, Flørenes VA, Davidson B (2012)
    MGST1 expression in serous ovarian carcinoma differs at various anatomic sites, but is unrelated to chemoresistance or survival
    Gynecol Oncol, 126 (3), 460-5
    DOI 10.1016/j.ygyno.2012.05.029, PubMed 22652154
  13. Hetland TE, Nymoen DA, Holth A, Brusegard K, Flørenes VA, Kærn J, Tropé CG, Davidson B (2012)
    Aurora B expression in metastatic effusions from advanced-stage ovarian serous carcinoma is predictive of intrinsic chemotherapy resistance
    Hum Pathol, 44 (5), 777-85
    DOI 10.1016/j.humpath.2012.08.002, PubMed 23114921
  14. Kaye S, Aamdal S, Jones R, Freyer G, Pujade-Lauraine E, de Vries EG, Barriuso J, Sandhu S, Tan DS, Hartog V, Kuenen B, Ruijter R, Kristensen GB, Nyakas M, Barrett S, Burke W, Pietersma D, Stuart M, Emeribe U, Boven E (2012)
    Phase I study of saracatinib (AZD0530) in combination with paclitaxel and/or carboplatin in patients with solid tumours
    Br J Cancer, 106 (11), 1728-34
    DOI 10.1038/bjc.2012.158, PubMed 22531637
  15. Knappskog S, Gansmo LB, Romundstad P, Bjørnslett M, Trovik J, Sommerfelt-Pettersen J, Løkkevik E, Norwegian Breast Cancer Group trial NBCG VI, Tollenaar RA, Seynaeve C, Devilee P, Salvesen HB, Dørum A, Hveem K, Vatten L, Lønning PE (2012)
    MDM2 promoter SNP344T>A (rs1196333) status does not affect cancer risk
    PLoS One, 7 (4), e36263
    DOI 10.1371/journal.pone.0036263, PubMed 22558411
  16. Lee CK, Simes RJ, Brown C, Gebski V, Pfisterer J, Swart AM, Berton-Rigaud D, Plante M, Skeie-Jensen T, Vergote I, Schauer C, Pisano C, Parma G, Baumann K, Ledermann JA, Pujade-Lauraine E, Bentley J, Kristensen G, Belau A, Nankivell M, Canzler U, Lord SJ, Kurzeder C, Friedlander M (2012)
    A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancer
    Ann Oncol, 24 (4), 937-43
    DOI 10.1093/annonc/mds538, PubMed 23104722
  17. Lindemann K, Christensen RD, Vergote I, Stuart G, Izquierdo MA, Kærn J, Havsteen H, Eisenhauer E, Ridderheim M, Lopez AB, Hirte H, Aavall-Lundquvist E, Vrdoljak E, Green J, Kristensen GB (2012)
    First-line treatment of advanced ovarian cancer with paclitaxel/carboplatin with or without epirubicin (TEC versus TC)--a gynecologic cancer intergroup study of the NSGO, EORTC GCG and NCIC CTG
    Ann Oncol, 23 (10), 2613-2619
    DOI 10.1093/annonc/mds060, PubMed 22539562
  18. Michelsen TM, Dørum A, Cvancarova M, Liavaag AH, Dahl AA (2012)
    Association between hysterectomy with ovarian preservation and cardiovascular disease in a Norwegian population-based sample
    Gynecol Obstet Invest, 75 (1), 61-7
    DOI 10.1159/000345072, PubMed 23220872
  19. Nielsen B, Albregtsen F, Kildal W, Abeler VM, Kristensen GB, Danielsen HE (2012)
    The prognostic value of adaptive nuclear texture features from patient gray level entropy matrices in early stage ovarian cancer
    Anal Cell Pathol (Amst), 35 (4), 305-14
    DOI 10.3233/ACP-2012-0065, PubMed 22596183
  20. Pradhan M, Davidson B, Abeler VM, Danielsen HE, Tropé CG, Kristensen GB, Risberg BÅ (2012)
    DNA ploidy may be a prognostic marker in stage I and II serous adenocarcinoma of the endometrium
    Virchows Arch, 461 (3), 291-8
    DOI 10.1007/s00428-012-1275-2, PubMed 22824999
  21. Tropé CG, Abeler VM, Kristensen GB (2012)
    Diagnosis and treatment of sarcoma of the uterus. A review
    Acta Oncol, 51 (6), 694-705
    DOI 10.3109/0284186X.2012.689111, PubMed 22793037
  22. Tropé CG, Elstrand MB, Sandstad B, Davidson B, Oksefjell H (2012)
    Neoadjuvant chemotherapy, interval debulking surgery or primary surgery in ovarian carcinoma FIGO stage IV?
    Eur J Cancer, 48 (14), 2146-54
    DOI 10.1016/j.ejca.2012.01.031, PubMed 22382201
  23. Tropé CG, Kaern J, Davidson B (2012)
    Borderline ovarian tumours
    Best Pract Res Clin Obstet Gynaecol, 26 (3), 325-36
    DOI 10.1016/j.bpobgyn.2011.12.006, PubMed 22321906
  24. Vaksman O, Hetland TE, Trope' CG, Reich R, Davidson B (2012)
    Argonaute, Dicer, and Drosha are up-regulated along tumor progression in serous ovarian carcinoma
    Hum Pathol, 43 (11), 2062-9
    DOI 10.1016/j.humpath.2012.02.016, PubMed 22647351
  25. Wagner U, Marth C, Largillier R, Kaern J, Brown C, Heywood M, Bonaventura T, Vergote I, Piccirillo MC, Fossati R, Gebski V, Lauraine EP (2012)
    Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients
    Br J Cancer, 107 (4), 588-91
    DOI 10.1038/bjc.2012.307, PubMed 22836511
  26. Weiss I, Trope CG, Reich R, Davidson B (2012)
    Hyaluronan synthase and hyaluronidase expression in serous ovarian carcinoma is related to anatomic site and chemotherapy exposure
    Int J Mol Sci, 13 (10), 12925-38
    DOI 10.3390/ijms131012925, PubMed 23202930

Publications 2011

  1. Andersen EK, Hole KH, Lund KV, Sundfør K, Kristensen GB, Lyng H, Malinen E (2011)
    Dynamic contrast-enhanced MRI of cervical cancers: temporal percentile screening of contrast enhancement identifies parameters for prediction of chemoradioresistance
    Int J Radiat Oncol Biol Phys, 82 (3), e485-92
    DOI 10.1016/j.ijrobp.2011.05.050, PubMed 22014954
  2. Bock AJ, Dong HP, Tropé CG, Staff AC, Risberg B, Davidson B (2011)
    Nucleoside transporters are widely expressed in ovarian carcinoma effusions
    Cancer Chemother Pharmacol, 69 (2), 467-75
    DOI 10.1007/s00280-011-1716-7, PubMed 21822668
  3. Bock AJ, Nymoen DA, Brenne K, Kærn J, Davidson B (2011)
    SCARA3 mRNA is overexpressed in ovarian carcinoma compared with breast carcinoma effusions
    Hum Pathol, 43 (5), 669-74
    DOI 10.1016/j.humpath.2011.06.003, PubMed 21855113
  4. Bock AJ, Tuft Stavnes H, Kærn J, Berner A, Staff AC, Davidson B (2011)
    Endoglin (CD105) expression in ovarian serous carcinoma effusions is related to chemotherapy status
    Tumour Biol, 32 (3), 589-96
    DOI 10.1007/s13277-011-0157-6, PubMed 21350924
  5. Brenne K, Nymoen DA, Hetland TE, Trope' CG, Davidson B (2011)
    Expression of the Ets transcription factor EHF in serous ovarian carcinoma effusions is a marker of poor survival
    Hum Pathol, 43 (4), 496-505
    DOI 10.1016/j.humpath.2011.05.023, PubMed 21855111
  6. Dahl AA, Gudbergsson SB, Dørum A, Fosså SD, Liavaag AH, Sørebø Ø (2011)
    "The impact of cancer scale" version 1: psychometric testing of the Norwegian translation in a heterogeneous sample of cancer survivors
    Qual Life Res, 21 (8), 1459-70
    DOI 10.1007/s11136-011-0053-y, PubMed 22045155
  7. Davidson B, Holth A, Moripen L, Trope' CG, Shih IeM (2011)
    Osteopontin expression in ovarian carcinoma effusions is related to improved clinical outcome
    Hum Pathol, 42 (7), 991-7
    DOI 10.1016/j.humpath.2010.10.013, PubMed 21315424
  8. Dong HP, Ree Rosnes AK, Bock AJ, Holth A, Flørenes VA, Trope' CG, Risberg B, Davidson B (2011)
    Flow cytometric measurement of cellular FLICE-inhibitory protein (c-FLIP) in ovarian carcinoma effusions
    Cytopathology, 22 (6), 373-82
    DOI 10.1111/j.1365-2303.2011.00929.x, PubMed 22032542
  9. Elstrand MB, Stavnes HT, Tropé CG, Davidson B (2011)
    Heat shock protein 90 is a putative therapeutic target in patients with recurrent advanced-stage ovarian carcinoma with serous effusions
    Hum Pathol, 43 (4), 529-35
    DOI 10.1016/j.humpath.2011.05.022, PubMed 21864883
  10. Gillet JP, Wang J, Calcagno AM, Green LJ, Varma S, Bunkholt Elstrand M, Trope CG, Ambudkar SV, Davidson B, Gottesman MM (2011)
    Clinical relevance of multidrug resistance gene expression in ovarian serous carcinoma effusions
    Mol Pharm, 8 (6), 2080-8
    DOI 10.1021/mp200240a, PubMed 21761824
  11. Gultekin M, Dursun P, Vranes B, Laky R, Bossart M, Grabowski JP, Piek JM, Manchanda R, Grimm C, Dallaku K, Babloyan S, Moisei A, Van Gorp T, Cadron I, Markov P, Micevska A, Halaska M, Steffensen KD, Gristsenko L, Nissi R, Lambaudie E, Tsitsishvili Z, Haidopoulos D, Tsolakidis D, Novak Z et al. (2011)
    Gynecologic oncology training systems in Europe: a report from the European network of young gynaecological oncologists
    Int J Gynecol Cancer, 21 (8), 1500-6
    DOI 10.1097/IGC.0b013e3182202d17, PubMed 21720256
  12. Halle C, Lando M, Sundfør K, Kristensen GB, Holm R, Lyng H (2011)
    Phosphorylation of EGFR measured with in situ proximity ligation assay: relationship to EGFR protein level and gene dosage in cervical cancer
    Radiother Oncol, 101 (1), 152-7
    DOI 10.1016/j.radonc.2011.05.052, PubMed 21680035
  13. Halle C, Lando M, Svendsrud DH, Clancy T, Holden M, Sundfør K, Kristensen GB, Holm R, Lyng H (2011)
    Membranous expression of ectodomain isoforms of the epidermal growth factor receptor predicts outcome after chemoradiotherapy of lymph node-negative cervical cancer
    Clin Cancer Res, 17 (16), 5501-12
    DOI 10.1158/1078-0432.CCR-11-0297, PubMed 21737508
  14. Hetland TE, Hellesylt E, Flørenes VA, Tropé C, Davidson B, Kærn J (2011)
    Class III β-tubulin expression in advanced-stage serous ovarian carcinoma effusions is associated with poor survival and primary chemoresistance
    Hum Pathol, 42 (7), 1019-26
    DOI 10.1016/j.humpath.2010.10.025, PubMed 21315408
  15. Kildal W, Micci F, Risberg B, Abeler VM, Kristensen GB, Heim S, Danielsen HE (2011)
    Genomic imbalances in endometrial adenocarcinomas - comparison of DNA ploidy, karyotyping and comparative genomic hybridization
    Mol Oncol, 6 (1), 98-107
    DOI 10.1016/j.molonc.2011.10.002, PubMed 22062770
  16. Kim G, Davidson B, Henning R, Wang J, Yu M, Annunziata C, Hetland T, Kohn EC (2011)
    Adhesion molecule protein signature in ovarian cancer effusions is prognostic of patient outcome
    Cancer, 118 (6), 1543-53
    DOI 10.1002/cncr.26449, PubMed 22009736
  17. Knappskog S, Bjørnslett M, Myklebust LM, Huijts PE, Vreeswijk MP, Edvardsen H, Guo Y, Zhang X, Yang M, Ylisaukko-Oja SK, Alhopuro P, Arola J, Tollenaar RA, van Asperen CJ, Seynaeve C, Staalesen V, Chrisanthar R, Løkkevik E, Salvesen HB, Evans DG, Newman WG, Lin D, Aaltonen LA, Børresen-Dale AL, Tell GS et al. (2011)
    The MDM2 promoter SNP285C/309G haplotype diminishes Sp1 transcription factor binding and reduces risk for breast and ovarian cancer in Caucasians
    Cancer Cell, 19 (2), 273-82
    DOI 10.1016/j.ccr.2010.12.019, PubMed 21316605
  18. Kurtz JE, Kaminsky MC, Floquet A, Veillard AS, Kimmig R, Dorum A, Elit L, Buck M, Petru E, Reed N, Scambia G, Varsellona N, Brown C, Pujade-Lauraine E, Gynecologic Cancer Intergroup (2011)
    Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-study
    Ann Oncol, 22 (11), 2417-2423
    DOI 10.1093/annonc/mdr001, PubMed 21402619
  19. Oksefjell H, Sandstad B, Tropé C (2011)
    The role of surgery in the second relapse of epithelial ovarian cancer. Selection criteria, morbidity and survival outcome
    Eur J Gynaecol Oncol, 32 (4), 369-76
    PubMed 21941955
  20. Paulsen T, Kærn J, Tropé C (2011)
    Improved 5-year disease-free survival for FIGO stage I epithelial ovarian cancer patients without tumor rupture during surgery
    Gynecol Oncol, 122 (1), 83-8
    DOI 10.1016/j.ygyno.2011.02.038, PubMed 21435701
  21. Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Kurzeder C, du Bois A, Sehouli J, Kimmig R, Stähle A, Collinson F, Essapen S, Gourley C, Lortholary A, Selle F, Mirza MR, Leminen A, Plante M, Stark D, Qian W, Parmar MK et al. (2011)
    A phase 3 trial of bevacizumab in ovarian cancer
    N Engl J Med, 365 (26), 2484-96
    DOI 10.1056/NEJMoa1103799, PubMed 22204725
  22. Pradhan M, Abeler VM, Danielsen HE, Sandstad B, Tropé CG, Kristensen GB, Risberg BÅ (2011)
    Prognostic importance of DNA ploidy and DNA index in stage I and II endometrioid adenocarcinoma of the endometrium
    Ann Oncol, 23 (5), 1178-1184
    DOI 10.1093/annonc/mdr368, PubMed 21965471
  23. Rustin GJ, Vergote I, Eisenhauer E, Pujade-Lauraine E, Quinn M, Thigpen T, du Bois A, Kristensen G, Jakobsen A, Sagae S, Greven K, Parmar M, Friedlander M, Cervantes A, Vermorken J, Gynecological Cancer Intergroup (2011)
    Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG)
    Int J Gynecol Cancer, 21 (2), 419-23
    DOI 10.1097/IGC.0b013e3182070f17, PubMed 21270624
  24. Sert MB, Abeler V (2011)
    Robot-assisted laparoscopic radical hysterectomy: comparison with total laparoscopic hysterectomy and abdominal radical hysterectomy; one surgeon's experience at the Norwegian Radium Hospital
    Gynecol Oncol, 121 (3), 600-4
    DOI 10.1016/j.ygyno.2011.02.002, PubMed 21353294
  25. Tian WJ, Chi DS, Sehouli J, Tropé CG, Jiang R, Ayhan A, Cormio G, Xing Y, Breitbach GP, Braicu EI, Rabbitt CA, Oksefjell H, Fotopoulou C, Meerpohl HG, du Bois A, Berek JS, Zang RY, Harter P (2011)
    A risk model for secondary cytoreductive surgery in recurrent ovarian cancer: an evidence-based proposal for patient selection
    Ann Surg Oncol, 19 (2), 597-604
    DOI 10.1245/s10434-011-1873-2, PubMed 21732142
  26. Vaksman O, Stavnes HT, Kaern J, Trope CG, Davidson B, Reich R (2011)
    miRNA profiling along tumour progression in ovarian carcinoma
    J Cell Mol Med, 15 (7), 1593-602
    DOI 10.1111/j.1582-4934.2010.01148.x, PubMed 20716115
  27. Vistad I, Cvancarova M, Kristensen GB, Fosså SD (2011)
    A study of chronic pelvic pain after radiotherapy in survivors of locally advanced cervical cancer
    J Cancer Surviv, 5 (2), 208-16
    DOI 10.1007/s11764-011-0172-z, PubMed 21259075
  28. Zang RY, Harter P, Chi DS, Sehouli J, Jiang R, Tropé CG, Ayhan A, Cormio G, Xing Y, Wollschlaeger KM, Braicu EI, Rabbitt CA, Oksefjell H, Tian WJ, Fotopoulou C, Pfisterer J, du Bois A, Berek JS (2011)
    Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort
    Br J Cancer, 105 (7), 890-6
    DOI 10.1038/bjc.2011.328, PubMed 21878937

Publications 2010

  1. Bock AJ, Stavnes HT, Kempf T, Tropè CG, Berner A, Davidson B, Staff AC (2010)
    Expression and clinical role of growth differentiation factor-15 in ovarian carcinoma effusions
    Int J Gynecol Cancer, 20 (9), 1448-55
    DOI 10.1111/IGC.0b013e3181f7d6be, PubMed 21336029
  2. Bunkholt Elstrand M, Dong HP, Ødegaard E, Holth A, Elloul S, Reich R, Tropé CG, Davidson B (2010)
    Mammalian target of rapamycin is a biomarker of poor survival in metastatic serous ovarian carcinoma
    Hum Pathol, 41 (6), 794-804
    DOI 10.1016/j.humpath.2009.09.017, PubMed 20153512
  3. Davidson B, Reich R, Trope CG, Wang TL, Shih IeM (2010)
    New determinates of disease progression and outcome in metastatic ovarian carcinoma
    Histol Histopathol, 25 (12), 1591-609
    DOI 10.14670/HH-25.1591, PubMed 20886439
  4. du Bois A, Herrstedt J, Hardy-Bessard AC, Müller HH, Harter P, Kristensen G, Joly F, Huober J, Avall-Lundqvist E, Weber B, Kurzeder C, Jelic S, Pujade-Lauraine E, Burges A, Pfisterer J, Gropp M, Staehle A, Wimberger P, Jackisch C, Sehouli J (2010)
    Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer
    J Clin Oncol, 28 (27), 4162-9
    DOI 10.1200/JCO.2009.27.4696, PubMed 20733132
  5. Elgaaen BV, Haug KB, Wang J, Olstad OK, Fortunati D, Onsrud M, Staff AC, Sauer T, Gautvik KM (2010)
    POLD2 and KSP37 (FGFBP2) correlate strongly with histology, stage and outcome in ovarian carcinomas
    PLoS One, 5 (11), e13837
    DOI 10.1371/journal.pone.0013837, PubMed 21079801
  6. Elloul S, Vaksman O, Stavnes HT, Trope CG, Davidson B, Reich R (2010)
    Mesenchymal-to-epithelial transition determinants as characteristics of ovarian carcinoma effusions
    Clin Exp Metastasis, 27 (3), 161-72
    DOI 10.1007/s10585-010-9315-2, PubMed 20213325
  7. Hogberg T, Signorelli M, de Oliveira CF, Fossati R, Lissoni AA, Sorbe B, Andersson H, Grenman S, Lundgren C, Rosenberg P, Boman K, Tholander B, Scambia G, Reed N, Cormio G, Tognon G, Clarke J, Sawicki T, Zola P, Kristensen G (2010)
    Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer--results from two randomised studies
    Eur J Cancer, 46 (13), 2422-31
    DOI 10.1016/j.ejca.2010.06.002, PubMed 20619634
  8. Hovland S, Arbyn M, Lie AK, Ryd W, Borge B, Berle EJ, Skomedal H, Kadima TM, Kyembwa L, Billay EM, Mukwege D, Chirimwami RB, Mvula TM, Snijders PJ, Meijer CJ, Karlsen F (2010)
    A comprehensive evaluation of the accuracy of cervical pre-cancer detection methods in a high-risk area in East Congo
    Br J Cancer, 102 (6), 957-65
    DOI 10.1038/sj.bjc.6605594, PubMed 20197765
  9. Micci F, Haugom L, Ahlquist T, Andersen HK, Abeler VM, Davidson B, Trope CG, Lothe RA, Heim S (2010)
    Genomic aberrations in borderline ovarian tumors
    J Transl Med, 8, 21
    DOI 10.1186/1479-5876-8-21, PubMed 20184781
  10. Micci F, Skotheim RI, Haugom L, Weimer J, Eibak AM, Abeler VM, Trope CG, Arnold N, Lothe RA, Heim S (2010)
    Array-CGH analysis of microdissected chromosome 19 markers in ovarian carcinoma identifies candidate target genes
    Genes Chromosomes Cancer, 49 (11), 1046-53
    DOI 10.1002/gcc.20813, PubMed 20725991
  11. Michelsen TM, Tonstad S, Pripp AH, Tropé CG, Dørum A (2010)
    Coronary heart disease risk profile in women who underwent salpingo-oophorectomy to prevent hereditary breast ovarian cancer
    Int J Gynecol Cancer, 20 (2), 233-9
    DOI 10.1111/igc.0b013e3181ca5ff4, PubMed 20169665
  12. Park JT, Chen X, Tropè CG, Davidson B, Shih IeM, Wang TL (2010)
    Notch3 overexpression is related to the recurrence of ovarian cancer and confers resistance to carboplatin
    Am J Pathol, 177 (3), 1087-94
    DOI 10.2353/ajpath.2010.100316, PubMed 20671266
  13. Pradhan M, Abeler VM, Davidson B, Kildal W, Nybøen A, Tropé CG, Risberg B, Danielsen HE (2010)
    DNA ploidy heterogeneity in endometrial carcinoma: comparison between curettage and hysterectomy specimens
    Int J Gynecol Pathol, 29 (6), 572-8
    DOI 10.1097/PGP.0b013e3181e2e8ee, PubMed 20881853
  14. Pradhan M, Risberg BA, Tropé CG, van de Rijn M, Gilks CB, Lee CH (2010)
    Gross genomic alterations and gene expression profiles of high- grade serous carcinoma of the ovary with and without BRCA1 inactivation
    BMC Cancer, 10, 493
    DOI 10.1186/1471-2407-10-493, PubMed 20843305
  15. Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, Gebski V, Heywood M, Vasey PA, Volgger B, Vergote I, Pignata S, Ferrero A, Sehouli J, Lortholary A, Kristensen G, Jackisch C, Joly F, Brown C, Le Fur N, du Bois A (2010)
    Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse
    J Clin Oncol, 28 (20), 3323-9
    DOI 10.1200/JCO.2009.25.7519, PubMed 20498395
  16. Rustin GJ, van der Burg ME, Griffin CL, Guthrie D, Lamont A, Jayson GC, Kristensen G, Mediola C, Coens C, Qian W, Parmar MK, Swart AM, MRC OV05, EORTC 55955 investigators (2010)
    Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial
    Lancet, 376 (9747), 1155-63
    DOI 10.1016/S0140-6736(10)61268-8, PubMed 20888993
  17. Sert B (2010)
    Robotic port-site and pelvic recurrences after robot-assisted laparoscopic radical hysterectomy for a stage IB1 adenocarcinoma of the cervix with negative lymph nodes
    Int J Med Robot, 6 (2), 132-5
    DOI 10.1002/rcs.295, PubMed 20049750
  18. Sert MB (2010)
    Comparison between robot-assisted laparoscopic radical hysterectomy (RRH) and abdominal radical hysterectomy (ARH): a case control study from EIO/Milan
    Gynecol Oncol, 117 (2), 389; author reply 389-90
    DOI 10.1016/j.ygyno.2010.01.032, PubMed 20153028
  19. Tropé CG (2010)
    Management of cervical carcinoma stage IV: comment.
    CME Journal of Gynecologic Oncology, 15 (1), 69-71
    PublikaID 105
  20. Tropé CG, Kristensen GB (2010)
    Surgery in treatment of recurrent cervical cancer
    CME Journal of Gynecologic Oncology, 15 (1), 33-39
    PublikaID 104
  21. Tropé CG, Kristensen GB (2010)
    The treatment of recurrent cervical cancer
    CME Journal of Gynecologic Oncology, 15 (1), 72-90
    PublikaID 106
  22. Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, Verheijen RH, van der Burg ME, Lacave AJ, Panici PB, Kenter GG, Casado A, Mendiola C, Coens C, Verleye L, Stuart GC, Pecorelli S, Reed NS, European Organization for Research and Treatment of Cancer-Gynaecological Cancer Group, NCIC Clinical Trials Group (2010)
    Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer
    N Engl J Med, 363 (10), 943-53
    DOI 10.1056/NEJMoa0908806, PubMed 20818904
  23. Verleye L, Ottevanger PB, Kristensen GB, Ehlen T, Johnson N, van der Burg ME, Reed NS, Verheijen RH, Gaarenstroom KN, Mosgaard B, Seoane JM, van der Velden J, Lotocki R, van der Graaf W, Penninckx B, Coens C, Stuart G, Vergote I (2010)
    Quality of pathology reports for advanced ovarian cancer: are we missing essential information? An audit of 479 pathology reports from the EORTC-GCG 55971/NCIC-CTG OV13 neoadjuvant trial
    Eur J Cancer, 47 (1), 57-64
    DOI 10.1016/j.ejca.2010.08.008, PubMed 20850296
  24. Wang Z, Trope CG, Flørenes VA, Suo Z, Nesland JM, Holm R (2010)
    Overexpression of CDC25B, CDC25C and phospho-CDC25C (Ser216) in vulvar squamous cell carcinomas are associated with malignant features and aggressive cancer phenotypes
    BMC Cancer, 10, 233
    DOI 10.1186/1471-2407-10-233, PubMed 20500813
  25. Yuan Y, Leszczynska M, Konstantinovsky S, Tropé CG, Reich R, Davidson B (2010)
    Netrin-4 is upregulated in breast carcinoma effusions compared to corresponding solid tumors
    Diagn Cytopathol, 39 (8), 562-6
    DOI 10.1002/dc.21424, PubMed 20730893

Publications 2009

  1. Abeler VM, Røyne O, Thoresen S, Danielsen HE, Nesland JM, Kristensen GB (2009)
    Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients
    Histopathology, 54 (3), 355-64
    DOI 10.1111/j.1365-2559.2009.03231.x, PubMed 19236512
  2. Baekelandt MM, Castiglione M, ESMO Guidelines Working Group (2009)
    Endometrial carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up
    Ann Oncol, 20 Suppl 4, 29-31
    DOI 10.1093/annonc/mdp120, PubMed 19454455
  3. Davidson B, Hadar R, Stavnes HT, Trope' CG, Reich R (2009)
    Expression of the peroxisome proliferator-activated receptors-alpha, -beta, and -gamma in ovarian carcinoma effusions is associated with poor chemoresponse and shorter survival
    Hum Pathol, 40 (5), 705-13
    DOI 10.1016/j.humpath.2008.09.019, PubMed 19157507
  4. Dong HP, Holth A, Kleinberg L, Ruud MG, Elstrand MB, Tropé CG, Davidson B, Risberg B (2009)
    Evaluation of cell surface expression of phosphatidylserine in ovarian carcinoma effusions using the annexin-V/7-AAD assay: clinical relevance and comparison with other apoptosis parameters
    Am J Clin Pathol, 132 (5), 756-62
    DOI 10.1309/AJCPAVFA8J3KHPRS, PubMed 19846818
  5. Elstrand MB, Kleinberg L, Kohn EC, Tropé CG, Davidson B (2009)
    Expression and clinical role of antiapoptotic proteins of the bag, heat shock, and Bcl-2 families in effusions, primary tumors, and solid metastases in ovarian carcinoma
    Int J Gynecol Pathol, 28 (3), 211-21
    DOI 10.1097/PGP.0b013e31818b0f5e, PubMed 19620938
  6. Kildal W, Pradhan M, Abeler VM, Kristensen GB, Danielsen HE (2009)
    Beta-catenin expression in uterine sarcomas and its relation to clinicopathological parameters
    Eur J Cancer, 45 (13), 2412-7
    DOI 10.1016/j.ejca.2009.06.017, PubMed 19622417
  7. Lando M, Holden M, Bergersen LC, Svendsrud DH, Stokke T, Sundfør K, Glad IK, Kristensen GB, Lyng H (2009)
    Gene dosage, expression, and ontology analysis identifies driver genes in the carcinogenesis and chemoradioresistance of cervical cancer
    PLoS Genet, 5 (11), e1000719
    DOI 10.1371/journal.pgen.1000719, PubMed 19911042
  8. Liavaag AH, Dørum A, Fosså SD, Tropé C, Dahl AA (2009)
    Morbidity associated with "self-rated health" in epithelial ovarian cancer survivors
    BMC Cancer, 9, 2
    DOI 10.1186/1471-2407-9-2, PubMed 19121203
  9. Liavaag AH, Tonstad S, Pripp AH, Tropé C, Dørum A (2009)
    Prevalence and determinants of metabolic syndrome and elevated Framingham risk score in epithelial ovarian cancer survivors: a controlled observational study
    Int J Gynecol Cancer, 19 (4), 634-40
    DOI 10.1111/IGC.0b013e3181a13058, PubMed 19509562
  10. Michelsen TM, Dørum A, Dahl AA (2009)
    A controlled study of mental distress and somatic complaints after risk-reducing salpingo-oophorectomy in women at risk for hereditary breast ovarian cancer
    Gynecol Oncol, 113 (1), 128-33
    DOI 10.1016/j.ygyno.2008.12.024, PubMed 19178933
  11. Michelsen TM, Dørum A, Tropé CG, Fosså SD, Dahl AA (2009)
    Fatigue and quality of life after risk-reducing salpingo-oophorectomy in women at increased risk for hereditary breast-ovarian cancer
    Int J Gynecol Cancer, 19 (6), 1029-36
    DOI 10.1111/IGC.0b013e3181a83cd5, PubMed 19820364
  12. Pradhan M, Davidson B, Tropé CG, Danielsen HE, Abeler VM, Risberg B (2009)
    Gross genomic alterations differ between serous borderline tumors and serous adenocarcinomas--an image cytometric DNA ploidy analysis of 307 cases with histogenetic implications
    Virchows Arch, 454 (6), 677-83
    DOI 10.1007/s00428-009-0778-y, PubMed 19421773
  13. Sert MB (2009)
    Robot assisted laparoscopic radical hysterectomy and pelvic lymphadenectomy with short and long term morbidity
    Gynecol Oncol, 115 (1), 164-165
    DOI 10.1016/j.ygyno.2009.05.028, PubMed 19539356
  14. Sert MB, Eraker R (2009)
    Robot-assisted laparoscopic surgery in gynaecological oncology; initial experience at Oslo Radium Hospital and 16 months follow-up
    Int J Med Robot, 5 (4), 410-4
    DOI 10.1002/rcs.272, PubMed 19569081
  15. Tropé C, Davidson B, Paulsen T, Abeler VM, Kaern J (2009)
    Diagnosis and treatment of borderline ovarian neoplasms "the state of the art"
    Eur J Gynaecol Oncol, 30 (5), 471-82
    PubMed 19899396
  16. Tropé C, Iversen OE (2009)
    [From wonder to alarm--the Tidsskriftet, the Nobel Prize and the HPV vaccine]
    Tidsskr Nor Laegeforen, 129 (7), 651; author reply 651
    DOI 10.4045/tidsskr.09.0067, PubMed 19337352
  17. Walker KJ, McGrattan K, Aas-Eng K, Smith AF (2009)
    Ultrasound guidance for peripheral nerve blockade
    Cochrane Database Syst Rev (4), CD006459
    DOI 10.1002/14651858.CD006459.pub2, PubMed 19821368

Publications 2008

  1. Baekelandt MM, Castiglione M, ESMO Guidelines Working Group (2008)
    Endometrial carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up
    Ann Oncol, 19 Suppl 2, ii19-20
    DOI 10.1093/annonc/mdn113, PubMed 18456753
  2. Dørum A, Tonstad S, Liavaag AH, Michelsen TM, Hildrum B, Dahl AA (2008)
    Bilateral oophorectomy before 50 years of age is significantly associated with the metabolic syndrome and Framingham risk score: a controlled, population-based study (HUNT-2)
    Gynecol Oncol, 109 (3), 377-83
    DOI 10.1016/j.ygyno.2008.02.025, PubMed 18407340
  3. Evans DG, Gaarenstroom KN, Stirling D, Shenton A, Maehle L, Dørum A, Steel M, Lalloo F, Apold J, Porteous ME, Vasen HF, van Asperen CJ, Moller P (2008)
    Screening for familial ovarian cancer: poor survival of BRCA1/2 related cancers
    J Med Genet, 46 (9), 593-7
    DOI 10.1136/jmg.2008.058248, PubMed 18413372
  4. Knopp S, Nesland JM, Tropé C (2008)
    SLNB and the importance of micrometastases in vulvar squamous cell carcinoma
    Surg Oncol, 17 (3), 219-25
    DOI 10.1016/j.suronc.2008.05.001, PubMed 18556194
  5. Lyng H, Lando M, Brøvig RS, Svendsrud DH, Johansen M, Galteland E, Brustugun OT, Meza-Zepeda LA, Myklebost O, Kristensen GB, Hovig E, Stokke T (2008)
    GeneCount: genome-wide calculation of absolute tumor DNA copy numbers from array comparative genomic hybridization data
    Genome Biol, 9 (5), R86
    DOI 10.1186/gb-2008-9-5-r86, PubMed 18500990
  6. Micci F, Haugom L, Abeler VM, Tropé CG, Danielsen HE, Heim S (2008)
    Consistent numerical chromosome aberrations in thecofibromas of the ovary
    Virchows Arch, 452 (3), 269-76
    DOI 10.1007/s00428-007-0561-x, PubMed 18188592
  7. Michelsen TM, Pripp AH, Tonstad S, Tropé CG, Dørum A (2008)
    Metabolic syndrome after risk-reducing salpingo-oophorectomy in women at high risk for hereditary breast ovarian cancer: a controlled observational study
    Eur J Cancer, 45 (1), 82-9
    DOI 10.1016/j.ejca.2008.09.028, PubMed 19008092
  8. Oksefjell H, Sandstad B, Tropé C (2008)
    The role of secondary cytoreduction in the management of the first relapse in epithelial ovarian cancer
    Ann Oncol, 20 (2), 286-93
    DOI 10.1093/annonc/mdn591, PubMed 18725390
  9. Oksefjell H, Sandstad B, Tropé C (2008)
    Is the watch and wait approach adequate after comprehensive surgical staging in invasive stage I epithelial ovarian cancer? The Norwegian Radium Hospital experience
    Eur J Gynaecol Oncol, 29 (6), 583-9
    PubMed 19115683
  10. Vistad I, Cvancarova M, Fosså SD, Kristensen GB (2008)
    Postradiotherapy morbidity in long-term survivors after locally advanced cervical cancer: how well do physicians' assessments agree with those of their patients?
    Int J Radiat Oncol Biol Phys, 71 (5), 1335-42
    DOI 10.1016/j.ijrobp.2007.12.030, PubMed 18355976
  11. Vistad I, Kristensen GB, Fosså SD, Dahl AA, Mørkrid L (2008)
    Intestinal malabsorption in long-term survivors of cervical cancer treated with radiotherapy
    Int J Radiat Oncol Biol Phys, 73 (4), 1141-7
    DOI 10.1016/j.ijrobp.2008.05.064, PubMed 18760883

Publications 2007

  1. Davidson B, Berner A, Trope' CG, Wang TL, Shih IeM (2007)
    Expression and clinical role of the bric-a-brac tramtrack broad complex/poxvirus and zinc protein NAC-1 in ovarian carcinoma effusions
    Hum Pathol, 38 (7), 1030-6
    DOI 10.1016/j.humpath.2006.12.009, PubMed 17391728
  2. Hoei-Hansen CE, Kraggerud SM, Abeler VM, Kaern J, Rajpert-De Meyts E, Lothe RA (2007)
    Ovarian dysgerminomas are characterised by frequent KIT mutations and abundant expression of pluripotency markers
    Mol Cancer, 6, 12
    DOI 10.1186/1476-4598-6-12, PubMed 17274819
  3. Holm R, Knopp S, Kumar R, Lee J, Nesland JM, Tropè C, Callen DF (2007)
    Expression of ZNF652, a novel zinc finger protein, in vulvar carcinomas and its relation to prognosis
    J Clin Pathol, 61 (1), 59-63
    DOI 10.1136/jcp.2006.045864, PubMed 17468294
  4. Liavaag AH, Dørum A, Bjøro T, Oksefjell H, Fosså SD, Tropé C, Dahl AA (2007)
    A controlled study of sexual activity and functioning in epithelial ovarian cancer survivors. A therapeutic approach
    Gynecol Oncol, 108 (2), 348-54
    DOI 10.1016/j.ygyno.2007.10.009, PubMed 17996925
  5. Liavaag AH, Dørum A, Fosså SD, Tropé C, Dahl AA (2007)
    Controlled study of fatigue, quality of life, and somatic and mental morbidity in epithelial ovarian cancer survivors: how lucky are the lucky ones?
    J Clin Oncol, 25 (15), 2049-56
    DOI 10.1200/JCO.2006.09.1769, PubMed 17513809
  6. Lyng H, Sitter B, Bathen TF, Jensen LR, Sundfør K, Kristensen GB, Gribbestad IS (2007)
    Metabolic mapping by use of high-resolution magic angle spinning 1H MR spectroscopy for assessment of apoptosis in cervical carcinomas
    BMC Cancer, 7, 11
    DOI 10.1186/1471-2407-7-11, PubMed 17233882
  7. Oksefjell H, Sandstad B, Tropé C (2007)
    Improved survival for stage IIIC ovarian cancer patients treated at the Norwegian Radium Hospital between 1984 and 2001
    Eur J Gynaecol Oncol, 28 (4), 256-62
    PubMed 17713088
  8. Paulsen T, Ree AH, Kaern J, Kjaerheim K, Bassarova A, Berner A, Haldorsen T, Tropé C, Nesland JM (2007)
    Expression of matrix metalloproteinase-2 in serous borderline ovarian tumors is associated with noninvasive implant formation
    Eur J Gynaecol Oncol, 28 (5), 356-63
    PubMed 17966213
  9. Sert B, Abeler V (2007)
    Robotic radical hysterectomy in early-stage cervical carcinoma patients, comparing results with total laparoscopic radical hysterectomy cases. The future is now?
    Int J Med Robot, 3 (3), 224-8
    DOI 10.1002/rcs.152, PubMed 17924449
  10. Tropé C, Kaern J (2007)
    Adjuvant chemotherapy for early-stage ovarian cancer: review of the literature
    J Clin Oncol, 25 (20), 2909-20
    DOI 10.1200/JCO.2007.11.1013, PubMed 17617522
  11. Vergote I, van der Zee AG, Kesic V, Sert B, Robova H, Rob L, Reed N, Luesley DM, Leblanc E, Hagen B, Gitsch G, du Bois A, di Vagno G, Colombo N, Beller U, Ayhan A, Jacobs I (2007)
    ESGO statement on cervical cancer vaccination
    Int J Gynecol Cancer, 17 (6), 1183-5
    DOI 10.1111/j.1525-1438.2007.01129.x, PubMed 17997794
  12. Vistad I, Fosså SD, Kristensen GB, Dahl AA (2007)
    Chronic fatigue and its correlates in long-term survivors of cervical cancer treated with radiotherapy
    BJOG, 114 (9), 1150-8
    DOI 10.1111/j.1471-0528.2007.01445.x, PubMed 17655733
  13. Wang Y, Kristensen GB, Børresen-Dale AL, Helland A (2007)
    TP53 mutations and codon 72 genotype--impact on survival among ovarian cancer patients
    Ann Oncol, 18 (5), 964-6
    DOI 10.1093/annonc/mdm134, PubMed 17488735
  14. Wu Q, Lind GE, Aasheim HC, Micci F, Silins I, Tropé CG, Nesland JM, Lothe RA, Suo Z (2007)
    The EPH receptor Bs (EPHBs) promoters are unmethylated in colon and ovarian cancers
    Epigenetics, 2 (4), 237-43
    DOI 10.4161/epi.2.4.5406, PubMed 18281782
  15. Wu Q, Lothe RA, Ahlquist T, Silins I, Tropé CG, Micci F, Nesland JM, Suo Z, Lind GE (2007)
    DNA methylation profiling of ovarian carcinomas and their in vitro models identifies HOXA9, HOXB5, SCGB3A1, and CRABP1 as novel targets
    Mol Cancer, 6, 45
    DOI 10.1186/1476-4598-6-45, PubMed 17623056

Publications 2006

  1. [No authors] (2006)
    An international perspective on surgical health care and education
    J Am Coll Surg, 204 (1), 148-57
    DOI 10.1016/j.jamcollsurg.2006.09.021, PubMed 17189123
  2. Aghmesheh M, Suo Z, Friedlander M, Nesland JM, Kaern J, Stewart M, Kconfab, Dorum A, Tucker KM, Buckley MF (2006)
    Chromosome 2q24.2 is lost in sporadic but not in BRCA1-associated ovarian carcinomas
    Pathology, 38 (2), 145-51
    DOI 10.1080/00313020600561526, PubMed 16680901
  3. Chi JT, Wang Z, Nuyten DS, Rodriguez EH, Schaner ME, Salim A, Wang Y, Kristensen GB, Helland A, Børresen-Dale AL, Giaccia A, Longaker MT, Hastie T, Yang GP, van de Vijver MJ, Brown PO (2006)
    Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers
    PLoS Med, 3 (3), e47
    DOI 10.1371/journal.pmed.0030047, PubMed 16417408
  4. Davidson B, Espina V, Steinberg SM, Flørenes VA, Liotta LA, Kristensen GB, Tropé CG, Berner A, Kohn EC (2006)
    Proteomic analysis of malignant ovarian cancer effusions as a tool for biologic and prognostic profiling
    Clin Cancer Res, 12 (3 Pt 1), 791-9
    DOI 10.1158/1078-0432.CCR-05-2516, PubMed 16467090
  5. Davidson B, Shafat I, Risberg B, Ilan N, Trope' CG, Vlodavsky I, Reich R (2006)
    Heparanase expression correlates with poor survival in metastatic ovarian carcinoma
    Gynecol Oncol, 104 (2), 311-9
    DOI 10.1016/j.ygyno.2006.08.045, PubMed 17030350
  6. Davidson B, Trope' CG, Wang TL, Shih IeM (2006)
    Expression of the chromatin remodeling factor Rsf-1 is upregulated in ovarian carcinoma effusions and predicts poor survival
    Gynecol Oncol, 103 (3), 814-9
    DOI 10.1016/j.ygyno.2006.05.042, PubMed 16844205
  7. Dong HP, Elstrand MB, Holth A, Silins I, Berner A, Trope CG, Davidson B, Risberg B (2006)
    NK- and B-cell infiltration correlates with worse outcome in metastatic ovarian carcinoma
    Am J Clin Pathol, 125 (3), 451-8
    DOI 10.1309/15B66DQMFYYM78CJ, PubMed 16613351
  8. Elloul S, Silins I, Tropé CG, Benshushan A, Davidson B, Reich R (2006)
    Expression of E-cadherin transcriptional regulators in ovarian carcinoma
    Virchows Arch, 449 (5), 520-8
    DOI 10.1007/s00428-006-0274-6, PubMed 17024425
  9. Gorovetz M, Baekelandt M, Berner A, Trope' CG, Davidson B, Reich R (2006)
    The clinical role of phospholipase A2 isoforms in advanced-stage ovarian carcinoma
    Gynecol Oncol, 103 (3), 831-40
    DOI 10.1016/j.ygyno.2006.06.042, PubMed 16919315
  10. Holm R, Knopp S, Suo Z, Tropè C, Nesland JM (2006)
    Expression of EphA2 and EphrinA-1 in vulvar carcinomas and its relation to prognosis
    J Clin Pathol, 60 (10), 1086-91
    DOI 10.1136/jcp.2006.041194, PubMed 17158642
  11. Knopp S, Holm R, Bjørge T, Tropé C, Nesland JM (2006)
    Cell cycle regulation in primary vulvar carcinomas and related lymph node metastases
    Histopathology, 49 (3), 311-2
    DOI 10.1111/j.1365-2559.2006.02457.x, PubMed 16918980
  12. Knudsen A, Monstad SE, Dørum A, Lønning PE, Salvesen HB, Drivsholm L, Aarseth JH, Vedeler CA (2006)
    Ri antibodies in patients with breast, ovarian or small cell lung cancer determined by a sensitive immunoprecipitation technique
    Cancer Immunol Immunother, 55 (10), 1280-4
    DOI 10.1007/s00262-006-0121-2, PubMed 16429314
  13. Kraus I, Molden T, Holm R, Lie AK, Karlsen F, Kristensen GB, Skomedal H (2006)
    Presence of E6 and E7 mRNA from human papillomavirus types 16, 18, 31, 33, and 45 in the majority of cervical carcinomas
    J Clin Microbiol, 44 (4), 1310-7
    DOI 10.1128/JCM.44.4.1310-1317.2006, PubMed 16597856
  14. Lyng H, Brøvig RS, Svendsrud DH, Holm R, Kaalhus O, Knutstad K, Oksefjell H, Sundfør K, Kristensen GB, Stokke T (2006)
    Gene expressions and copy numbers associated with metastatic phenotypes of uterine cervical cancer
    BMC Genomics, 7, 268
    DOI 10.1186/1471-2164-7-268, PubMed 17054779
  15. Monstad SE, Storstein A, Dørum A, Knudsen A, Lønning PE, Salvesen HB, Aarseth JH, Vedeler CA (2006)
    Yo antibodies in ovarian and breast cancer patients detected by a sensitive immunoprecipitation technique
    Clin Exp Immunol, 144 (1), 53-8
    DOI 10.1111/j.1365-2249.2006.03031.x, PubMed 16542365
  16. Oksefjell H, Sandstad B, Trope C (2006)
    Ovarian cancer stage IIIC. Consequences of treatment level on overall and progression-free survival
    Eur J Gynaecol Oncol, 27 (3), 209-14
    PubMed 16800244
  17. Paulsen T, Kaern J, Kjaerheim K, Haldorsen T, Tropé C (2006)
    Influence of interval between primary surgery and chemotherapy on short-term survival of patients with advanced ovarian, tubal or peritoneal cancer
    Gynecol Oncol, 102 (3), 447-52
    DOI 10.1016/j.ygyno.2006.01.035, PubMed 16516277
  18. Paulsen T, Kjaerheim K, Kaern J, Tretli S, Tropé C (2006)
    Improved short-term survival for advanced ovarian, tubal, and peritoneal cancer patients operated at teaching hospitals
    Int J Gynecol Cancer, 16 Suppl 1, 11-7
    DOI 10.1111/j.1525-1438.2006.00319.x, PubMed 16515561
  19. Pradhan M, Abeler VM, Danielsen HE, Tropé CG, Risberg BA (2006)
    Image cytometry DNA ploidy correlates with histological subtypes in endometrial carcinomas
    Mod Pathol, 19 (9), 1227-35
    DOI 10.1038/modpathol.3800641, PubMed 16729014
  20. Sert B, Abeler VM, Dørum A, Trope CG (2006)
    A new approach to treatment of early-stage cervical carcinoma: entire laparoscopic abdominal radical hysterectomy with bilateral pelvic lymphadenectomy without vaginal cuff closure--case reports
    Eur J Gynaecol Oncol, 27 (5), 513-8
    PubMed 17139990
  21. Tropé C, Kaern J (2006)
    Primary surgery for ovarian cancer
    Eur J Surg Oncol, 32 (8), 844-52
    DOI 10.1016/j.ejso.2006.03.036, PubMed 16677797
  22. Wang Y, Kringen P, Kristensen GB, Holm R, Baekelandt MMO, Olivier M, Skomedal H, Hainaut P, Trope CG, Abeler VM, Nesland JM, Borresen-Dale AL, Helland A (2006)
    Effect of the codon 72 polymorphism (c.215G > C, p.Arg72Pro) in combination with somatic sequence variants in the TP53 gene on survival in patients with advanced ovarian carcinoma (vol 24, pg 21, 2004)
    Hum. Mutat., 27 (2), 209-210
  23. Wu Q, Suo Z, Kristensen GB, Baekelandt M, Nesland JM (2006)
    The prognostic impact of EphB2/B4 expression on patients with advanced ovarian carcinoma
    Gynecol Oncol, 102 (1), 15-21
    DOI 10.1016/j.ygyno.2005.11.034, PubMed 16499955

Publications 2005

  1. Benetkiewicz M, Wang Y, Schaner M, Wang P, Mantripragada KK, Buckley PG, Kristensen G, Børresen-Dale AL, Dumanski JP (2005)
    High-resolution gene copy number and expression profiling of human chromosome 22 in ovarian carcinomas
    Genes Chromosomes Cancer, 42 (3), 228-37
    DOI 10.1002/gcc.20128, PubMed 15578687
  2. Chen YC, Pohl G, Wang TL, Morin PJ, Risberg B, Kristensen GB, Yu A, Davidson B, Shih IeM (2005)
    Apolipoprotein E is required for cell proliferation and survival in ovarian cancer
    Cancer Res, 65 (1), 331-7
    PubMed 15665311
  3. Davidson B, Elstrand MB, McMaster MT, Berner A, Kurman RJ, Risberg B, Trope CG, Shih IeM (2005)
    HLA-G expression in effusions is a possible marker of tumor susceptibility to chemotherapy in ovarian carcinoma
    Gynecol Oncol, 96 (1), 42-7
    DOI 10.1016/j.ygyno.2004.09.049, PubMed 15589578
  4. Dørum A, Blom GP, Ekerhovd E, Granberg S (2005)
    Prevalence and histologic diagnosis of adnexal cysts in postmenopausal women: an autopsy study
    Am J Obstet Gynecol, 192 (1), 48-54
    DOI 10.1016/j.ajog.2004.07.038, PubMed 15672002
  5. Elloul S, Elstrand MB, Nesland JM, Tropé CG, Kvalheim G, Goldberg I, Reich R, Davidson B (2005)
    Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma
    Cancer, 103 (8), 1631-43
    DOI 10.1002/cncr.20946, PubMed 15742334
  6. Han L, Dong Z, Qiao Y, Kristensen GB, Holm R, Nesland JM, Suo Z (2005)
    The clinical significance of EphA2 and Ephrin A-1 in epithelial ovarian carcinomas
    Gynecol Oncol, 99 (2), 278-86
    DOI 10.1016/j.ygyno.2005.06.036, PubMed 16061279
  7. Kaern J, Aghmesheh M, Nesland JM, Danielsen HE, Sandstad B, Friedlander M, Tropé C (2005)
    Prognostic factors in ovarian carcinoma stage III patients. Can biomarkers improve the prediction of short- and long-term survivors?
    Int J Gynecol Cancer, 15 (6), 1014-22
    DOI 10.1111/j.1525-1438.2005.00185.x, PubMed 16343177
  8. Kildal W, Risberg B, Abeler VM, Kristensen GB, Sudbø J, Nesland JM, Danielsen HE (2005)
    beta-catenin expression, DNA ploidy and clinicopathological features in ovarian cancer: a study in 253 patients
    Eur J Cancer, 41 (8), 1127-34
    DOI 10.1016/j.ejca.2005.01.022, PubMed 15911235
  9. Knopp S, Bjørge T, Nesland JM, Tropé C, Holm R (2005)
    Cyclins D1, D3, E, and A in vulvar carcinoma patients
    Gynecol Oncol, 97 (3), 733-9
    DOI 10.1016/j.ygyno.2005.03.025, PubMed 15894358
  10. Kringen P, Wang Y, Dumeaux V, Nesland JM, Kristensen G, Borresen-Dale AL, Dorum A (2005)
    TP53 mutations in ovarian carcinomas from sporadic cases and carriers of two distinct BRCA1 founder mutations; relation to age at diagnosis and survival
    BMC Cancer, 5, 134
    DOI 10.1186/1471-2407-5-134, PubMed 16229746
  11. Paulsen T, Kaern J, Kjaerheim K, Tropé C, Tretli S (2005)
    Symptoms and referral of women with epithelial ovarian tumors
    Int J Gynaecol Obstet, 88 (1), 31-7
    DOI 10.1016/j.ijgo.2004.09.008, PubMed 15617702
  12. Reich R, Vintman L, Nielsen S, Kaern J, Bedrossian C, Berner A, Davidson B (2005)
    Differential expression of the 67 kilodalton laminin receptor in epithelioid malignant mesothelioma and carcinomas that spread to serosal cavities
    Diagn Cytopathol, 33 (5), 332-7
    DOI 10.1002/dc.20296, PubMed 16240397
  13. Schaner ME, Davidson B, Skrede M, Reich R, Flørenes VA, Risberg B, Berner A, Goldberg I, Givant-Horwitz V, Tropè CG, Kristensen GB, Nesland JM, Børresen-Dale AL (2005)
    Variation in gene expression patterns in effusions and primary tumors from serous ovarian cancer patients
    Mol Cancer, 4, 26
    DOI 10.1186/1476-4598-4-26, PubMed 16042759
  14. Shih IeM, Sheu JJ, Santillan A, Nakayama K, Yen MJ, Bristow RE, Vang R, Parmigiani G, Kurman RJ, Trope CG, Davidson B, Wang TL (2005)
    Amplification of a chromatin remodeling gene, Rsf-1/HBXAP, in ovarian carcinoma
    Proc Natl Acad Sci U S A, 102 (39), 14004-9
    DOI 10.1073/pnas.0504195102, PubMed 16172393
  15. Stevens EV, Raffeld M, Espina V, Kristensen GB, Trope' CG, Kohn EC, Davidson B (2005)
    Expression of xeroderma pigmentosum A protein predicts improved outcome in metastatic ovarian carcinoma
    Cancer, 103 (11), 2313-9
    DOI 10.1002/cncr.21031, PubMed 15844177
  16. Van de Putte G, Holm R, Lie AK, Baekelandt M, Kristensen GB (2005)
    Markers of apoptosis in stage IB squamous cervical carcinoma
    J Clin Pathol, 58 (6), 590-4
    DOI 10.1136/jcp.2004.021220, PubMed 15917408
  17. Van de Putte G, Lie AK, Vach W, Baekelandt M, Kristensen GB (2005)
    Risk grouping in stage IB squamous cell cervical carcinoma
    Gynecol Oncol, 99 (1), 106-12
    DOI 10.1016/j.ygyno.2005.05.026, PubMed 16137752
  18. Van de Putte G, Vach W (2005)
    Re: "P63 and EGFR as prognostic predictors in stage IIB radiation-treated cervical squamous cell carcinoma"
    Gynecol Oncol, 98 (2), 335-6
    DOI 10.1016/j.ygyno.2004.09.011, PubMed 16039312
  19. Wang Y, Helland A, Holm R, Kristensen GB, Børresen-Dale AL (2005)
    PIK3CA mutations in advanced ovarian carcinomas
    Hum Mutat, 25 (3), 322
    DOI 10.1002/humu.9316, PubMed 15712344
  20. Wang Y, Kristensen GB, Helland A, Nesland JM, Børresen-Dale AL, Holm R (2005)
    Protein expression and prognostic value of genes in the erb-b signaling pathway in advanced ovarian carcinomas
    Am J Clin Pathol, 124 (3), 392-401
    DOI 10.1309/BL7E-MW66-LQX6-GFRP, PubMed 16191507
  21. Ødegaard E, Staff AC, Kaern J, Flørenes VA, Kopolovic J, Tropé CG, Abeler VM, Reich R, Davidson B (2005)
    The AP-2gamma transcription factor is upregulated in advanced-stage ovarian carcinoma
    Gynecol Oncol, 100 (3), 462-8
    DOI 10.1016/j.ygyno.2005.09.022, PubMed 16216317

Publications 2004

  1. Aghmesheh M, Nesland JM, Kaern J, Dorum A, Edwards L, Byth K, Friedlander M, Jackson P, Tucker KM, Russell PJ (2004)
    No differences in p53 mutation frequencies between BRCA1-associated and sporadic ovarian cancers
    Gynecol Oncol, 95 (3), 430-6
    DOI 10.1016/j.ygyno.2004.08.035, PubMed 15581943
  2. Bjørge T, Lie AK, Hovig E, Gislefoss RE, Hansen S, Jellum E, Langseth H, Nustad K, Tropé CG, Dørum A (2004)
    BRCA1 mutations in ovarian cancer and borderline tumours in Norway: a nested case-control study
    Br J Cancer, 91 (10), 1829-34
    DOI 10.1038/sj.bjc.6602199, PubMed 15477862
  3. Davidson B, Alejandro E, Flørenes VA, Goderstad JM, Risberg B, Kristensen GB, Trope CG, Kohn EC (2004)
    Granulin-epithelin precursor is a novel prognostic marker in epithelial ovarian carcinoma
    Cancer, 100 (10), 2139-47
    DOI 10.1002/cncr.20219, PubMed 15139056
  4. Davidson B, Goldberg I, Tell L, Vigdorchik S, Baekelandt M, Berner A, Kristensen GB, Reich R, Kopolovic J (2004)
    The clinical role of the PEA3 transcription factor in ovarian and breast carcinoma in effusions
    Clin Exp Metastasis, 21 (3), 191-9
    DOI 10.1023/b:clin.0000037703.37275.35, PubMed 15387369
  5. Davidson B, Reich R, Lazarovici P, Flørenes VA, Risberg B, Nielsen S, Sert B, Bedrossian C (2004)
    Expression of the nerve growth factor receptors TrkA and p75 in malignant mesothelioma
    Lung Cancer, 44 (2), 159-65
    DOI 10.1016/j.lungcan.2003.11.014, PubMed 15084380
  6. Ekstrøm PO, Bjørge T, Dørum A, Longva AS, Heintz KM, Warren DJ, Hansen S, Gislefoss RE, Hovig E (2004)
    Determination of hereditary mutations in the BRCA1 gene using archived serum samples and capillary electrophoresis
    Anal Chem, 76 (15), 4406-9
    DOI 10.1021/ac049788k, PubMed 15283579
  7. Givant-Horwitz V, Davidson B, Goderstad JM, Nesland JM, Tropé CG, Reich R (2004)
    The PAC-1 dual specificity phosphatase predicts poor outcome in serous ovarian carcinoma
    Gynecol Oncol, 93 (2), 517-23
    DOI 10.1016/j.ygyno.2004.03.009, PubMed 15099972
  8. Kildal W, Kaern J, Kraggerud SM, Abeler VM, Sudbø J, Tropè CG, Lothe RA, Danielsen HE (2004)
    Evaluation of genomic changes in a large series of malignant ovarian germ cell tumors--relation to clinicopathologic variables
    Cancer Genet Cytogenet, 155 (1), 25-32
    DOI 10.1016/j.cancergencyto.2004.02.010, PubMed 15527899
  9. Knopp S, Bjørge T, Nesland JM, Tropé C, Scheistrøen M, Holm R (2004)
    p16INK4a and p21Waf1/Cip1 expression correlates with clinical outcome in vulvar carcinomas
    Gynecol Oncol, 95 (1), 37-45
    DOI 10.1016/j.ygyno.2004.07.026, PubMed 15385108
  10. Kristensen G, Tropé C (2004)
    Endometrial cancer: the management of high-risk disease
    Curr Oncol Rep, 6 (6), 471-5
    DOI 10.1007/s11912-004-0078-2, PubMed 15485617
  11. Mebis J, De Raeve H, Baekelandt M, Tjalma WA, Vermorken JB (2004)
    Primary ovarian small cell carcinoma of the pulmonary type: a case report and review of the literature
    Eur J Gynaecol Oncol, 25 (2), 239-41
    PubMed 15032292
  12. Van de Putte G, Kristensen GB, Baekelandt M, Lie AK, Holm R (2004)
    E-cadherin and catenins in early squamous cervical carcinoma
    Gynecol Oncol, 94 (2), 521-7
    DOI 10.1016/j.ygyno.2004.05.046, PubMed 15297198
  13. Van de Putte G, Kristensen GB, Lie AK, Baekelandt M, Holm R (2004)
    Cyclins and proliferation markers in early squamous cervical carcinoma
    Gynecol Oncol, 92 (1), 40-6
    DOI 10.1016/j.ygyno.2003.10.022, PubMed 14751136
  14. Van de Putte GV, Holm R, Lie AK, Trope CG, Kristensen GB (2004)
    Expression of p27, p21, and p16 protein in early squamous cervical cancer and its relation to prognosis (vol 89, pg 140, 2003)
    Gynecol. Oncol., 92 (2), 730
  15. Wang Y, Helland A, Holm R, Skomedal H, Abeler VM, Danielsen HE, Tropé CG, Børresen-Dale AL, Kristensen GB (2004)
    TP53 mutations in early-stage ovarian carcinoma, relation to long-term survival
    Br J Cancer, 90 (3), 678-85
    DOI 10.1038/sj.bjc.6601537, PubMed 14760384
  16. Wang Y, Kringen P, Kristensen GB, Holm R, Baekelandt MM, Olivier M, Skomedal H, Hainaut P, Tropé CG, Abeler VM, Nesland JM, Børresen-Dale AL, Helland A (2004)
    Effect of the codon 72 polymorphism (c.215G>C, p.Arg72Pro) in combination with somatic sequence variants in the TP53 gene on survival in patients with advanced ovarian carcinoma
    Hum Mutat, 24 (1), 21-34
    DOI 10.1002/humu.20055, PubMed 15221786
  17. Wu D, Qiao Y, Kristensen GB, Li S, Troen G, Holm R, Nesland JM, Suo Z (2004)
    Prognostic significance of dysadherin expression in cervical squamous cell carcinoma
    Pathol Oncol Res, 10 (4), 212-8
    DOI 10.1007/BF03033763, PubMed 15619642
  18. Wu D, Suo Z, Kristensen GB, Li S, Troen G, Holm R, Nesland JM (2004)
    Prognostic value of EphA2 and EphrinA-1 in squamous cell cervical carcinoma
    Gynecol Oncol, 94 (2), 312-9
    DOI 10.1016/j.ygyno.2004.05.019, PubMed 15297167
  19. Xi Z, Kaern J, Davidson B, Klokk TI, Risberg B, Tropé C, Saatcioglu F (2004)
    Kallikrein 4 is associated with paclitaxel resistance in ovarian cancer
    Gynecol Oncol, 94 (1), 80-5
    DOI 10.1016/j.ygyno.2004.03.044, PubMed 15262123

Publications 2003

  1. Alfsen GC, Reed W, Sandstad B, Kristensen GB, Abeler VM (2003)
    The prognostic impact of cyclin dependent kinase inhibitors p21WAF1, p27Kip1, and p16INK4/MTS1 in adenocarcinomas of the uterine cervix: an immunohistochemical evaluation of expression patterns in population-based material from 142 patients with international federation of gynecology and obstetrics stage I and II adenocarcinoma
    Cancer, 98 (9), 1880-9
    DOI 10.1002/cncr.11727, PubMed 14584070
  2. Baekelandt M (2003)
    The potential role of neoadjuvant chemotherapy in advanced ovarian cancer
    Int J Gynecol Cancer, 13 Suppl 2, 163-8
    DOI 10.1111/j.1525-1438.2003.13354.x, PubMed 14656274
  3. Colombo N, du Bois A, Kristensen G, Ledermann J, Torri V, ICON4 Collaborators (2003)
    ICON4/AGO-OVAR-2.2: questions about trial design, cost-effectiveness, and clinical benefit - Reply
    Lancet, 362 (9392), 1334
  4. Davidson B, Givant-Horwitz V, Lazarovici P, Risberg B, Nesland JM, Trope CG, Schaefer E, Reich R (2003)
    Matrix metalloproteinases (MMP), EMMPRIN (extracellular matrix metalloproteinase inducer) and mitogen-activated protein kinases (MAPK): co-expression in metastatic serous ovarian carcinoma
    Clin Exp Metastasis, 20 (7), 621-31
    DOI 10.1023/a:1027347932543, PubMed 14669793
  5. Davidson B, Goldberg I, Berner A, Kristensen GB, Reich R (2003)
    EMMPRIN (extracellular matrix metalloproteinase inducer) is a novel marker of poor outcome in serous ovarian carcinoma
    Clin Exp Metastasis, 20 (2), 161-9
    DOI 10.1023/a:1022696012668, PubMed 12705637
  6. Davidson B, Reich R, Lazarovici P, Nesland JM, Skrede M, Risberg B, Tropé CG, Flørenes VA (2003)
    Expression and activation of the nerve growth factor receptor TrkA in serous ovarian carcinoma
    Clin Cancer Res, 9 (6), 2248-59
    PubMed 12796393
  7. Einhorn N, Tropé C, Ridderheim M, Boman K, Sorbe B, Cavallin-Ståhl E (2003)
    A systematic overview of radiation therapy effects in uterine cancer (corpus uteri)
    Acta Oncol, 42 (5-6), 557-61
    DOI 10.1080/02841860310014417, PubMed 14596513
  8. Einhorn N, Tropé C, Ridderheim M, Boman K, Sorbe B, Cavallin-Ståhl E (2003)
    A systematic overview of radiation therapy effects in ovarian cancer
    Acta Oncol, 42 (5-6), 562-6
    DOI 10.1080/02841860310014426, PubMed 14596514
  9. Einhorn N, Tropé C, Ridderheim M, Boman K, Sorbe B, Cavallin-Ståhl E (2003)
    A systematic overview of radiation therapy effects in cervical cancer (cervix uteri)
    Acta Oncol, 42 (5-6), 546-56
    DOI 10.1080/02841860310014660, PubMed 14596512
  10. Givant-Horwitz V, Davidson B, Lazarovici P, Schaefer E, Nesland JM, Tropé CG, Reich R (2003)
    Mitogen-activated protein kinases (MAPK) as predictors of clinical outcome in serous ovarian carcinoma in effusions
    Gynecol Oncol, 91 (1), 160-72
    DOI 10.1016/s0090-8258(03)00434-7, PubMed 14529677
  11. Givant-Horwitz V, Davidson B, van de Putte G, Dong HP, Goldberg I, Amir S, Kristensen GB, Reich R (2003)
    Expression of the 67 kDa laminin receptor and the alpha6 integrin subunit in serous ovarian carcinoma
    Clin Exp Metastasis, 20 (7), 599-609
    DOI 10.1023/a:1027340208536, PubMed 14669791
  12. Kildal W, Kraggerud SM, Abeler VM, Heim S, Tropé CG, Kristensen GB, Risberg B, Lothe RA, Danielsen HE (2003)
    Genome profiles of bilateral dysgerminomas, a unilateral gonadoblastoma, and a metastasis from a 46, XY phenotypic female
    Hum Pathol, 34 (9), 946-9
    DOI 10.1016/s0046-8177(03)00345-9, PubMed 14562293
  13. Kohn EC, Fidler IJ, Fishman D, Jaffe R, Liotta LA, Van Trappen P, Mills GB, Trope C (2003)
    Discussion: Metastasis and angiogenesis in epithelial ovarian cancer
    Gynecol. Oncol., 88 (1), S37-S42
  14. Kristensen GB, Kildal W, Abeler VM, Kaern J, Vergote I, Tropé CG, Danielsen HE (2003)
    Large-scale genomic instability predicts long-term outcome for women with invasive stage I ovarian cancer
    Ann Oncol, 14 (10), 1494-500
    DOI 10.1093/annonc/mdg403, PubMed 14504048
  15. Kristensen GB, Vergote I, Stuart G, Del Campo JM, Kaern J, Lopez AB, Eisenhauer E, Aavall-Lundquist E, Ridderheim M, Havsteen H, Mirza MR, Scheistroen M, Vrdoljak E (2003)
    First-line treatment of ovarian cancer FIGO stages IIb-IV with paclitaxel/epirubicin/carboplatin versus paclitaxel/carboplatin
    Int J Gynecol Cancer, 13 Suppl 2, 172-7
    DOI 10.1111/j.1525-1438.2003.13363.x, PubMed 14656276
  16. Kristiansen M, Helland A, Kristensen GB, Olsen AO, Lønning PE, Børresen-Dale AL, Ørstavik KH (2003)
    X chromosome inactivation in cervical cancer patients
    Cancer Genet Cytogenet, 146 (1), 73-6
    DOI 10.1016/s0165-4608(03)00152-3, PubMed 14499700
  17. Parmar MK, Ledermann JA, Colombo N, du Bois A, Delaloye JF, Kristensen GB, Wheeler S, Swart AM, Qian W, Torri V, Floriani I, Jayson G, Lamont A, Tropé C, ICON and AGO Collaborators (2003)
    Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial
    Lancet, 361 (9375), 2099-106
    DOI 10.1016/s0140-6736(03)13718-x, PubMed 12826431
  18. Thorstensen L, Holm R, Lothe RA, Tropé C, Carvalho B, Sobrinho-Simoes M, Seruca R (2003)
    WNT-inducible signaling pathway protein 3, WISP-3, is mutated in microsatellite unstable gastrointestinal carcinomas but not in endometrial carcinomas
    Gastroenterology, 124 (1), 270-1
    DOI 10.1053/gast.2003.50034, PubMed 12512062
  19. Tropé C, Kaern J, Saeter G, Gore M (2003)
    [Paclitaxel should be included in standard therapy of ovarian carcinoma]
    Tidsskr Nor Laegeforen, 123 (21), 3083-4
    PubMed 14618184
  20. van de Putte G, Holm R, Lie AK, Tropé CG, Kristensen GB (2003)
    Expression of p27, p21, and p16 protein in early squamous cervical cancer and its relation to prognosis
    Gynecol Oncol, 89 (1), 140-7
    DOI 10.1016/s0090-8258(03)00010-6, PubMed 12694668
  21. Van de Putte G, Holm R, Lie AK, Trope CG, Kristensen GB (2003)
    Expression of p27, p21, and p16 protein in early squamous cervical cancer and its relation to prognosis (vol 89, pg 140, 2003)
    Gynecol. Oncol., 90 (1), 231

Publications 2002

  1. Baekelandt M (2002)
    Irofulven (MGI Pharma)
    Curr Opin Investig Drugs, 3 (10), 1517-26
    PubMed 12431030
  2. Baekelandt M (2002)
    Hormonal treatment of endometrial carcinoma
    Expert Rev Anticancer Ther, 2 (1), 106-12
    DOI 10.1586/14737140.2.1.106, PubMed 12113059
  3. Bjørge T, Abeler VM, Sundfør K, Tropé CG, Kaern J (2002)
    Gestational trophoblastic tumors in Norway, 1968-1997: patient characteristics, treatment, and prognosis
    Gynecol Oncol, 87 (1), 71-6
    DOI 10.1006/gyno.2002.6801, PubMed 12468345
  4. Bjørge T, Engeland A, Luostarinen T, Mork J, Gislefoss RE, Jellum E, Koskela P, Lehtinen M, Pukkala E, Thoresen SØ, Dillner J (2002)
    Human papillomavirus infection as a risk factor for anal and perianal skin cancer in a prospective study
    Br J Cancer, 87 (1), 61-4
    DOI 10.1038/sj.bjc.6600350, PubMed 12085257
  5. Davidson B, Goldberg I, Givant-Horwitz V, Nesland JM, Berner A, Bryne M, Risberg B, Kopolovic J, Kristensen GB, Tropé CG, van de Putte G, Reich R (2002)
    Caveolin-1 expression in ovarian carcinoma is MDR1 independent
    Am J Clin Pathol, 117 (2), 225-34
    DOI 10.1309/u40r-1bn4-6kj3-bdg3, PubMed 11863219
  6. Davidson B, Reich R, Kopolovic J, Berner A, Nesland JM, Kristensen GB, Tropé CG, Bryne M, Risberg B, van de Putte G, Goldberg I (2002)
    Interleukin-8 and vascular endothelial growth factor mRNA and protein levels are down-regulated in ovarian carcinoma cells in serous effusions
    Clin Exp Metastasis, 19 (2), 135-44
    DOI 10.1023/a:1014582911680, PubMed 11964077
  7. Kaern J, Baekelandt M, Tropé CG (2002)
    A phase II study of weekly paclitaxel in platinum and paclitaxel-resistant ovarian cancer patients
    Eur J Gynaecol Oncol, 23 (5), 383-9
    PubMed 12440808
  8. Karbova E, Davidson B, Metodiev K, Tropé CG, Nesland JM (2002)
    Adenomatous polyposis coli (APC) protein expression in primary and metastatic serous ovarian carcinoma
    Int J Surg Pathol, 10 (3), 175-80
    DOI 10.1177/106689690201000302, PubMed 12232570
  9. Marth C, Kisic J, Kaern J, Tropé C, Fodstad Ø (2002)
    Circulating tumor cells in the peripheral blood and bone marrow of patients with ovarian carcinoma do not predict prognosis
    Cancer, 94 (3), 707-12
    DOI 10.1002/cncr.10250, PubMed 11857303
  10. Scheistrøen M, Nesland JM, Tropé C (2002)
    Have patients with early squamous carcinoma of the vulva been overtreated in the past? The Norwegian experience 1977-1991
    Eur J Gynaecol Oncol, 23 (2), 93-103
    PubMed 12013120
  11. Tropé C (2002)
    [Mass screening against endometrial cancer?]
    Tidsskr Nor Laegeforen, 122 (18), 1767
    PubMed 12362684
  12. Tropé C (2002)
    [Laparoscopic surgery in endometrial carcinoma]
    Tidsskr Nor Laegeforen, 122 (25), 2429
    PubMed 12448107

Publications 2001

  1. Alfsen GC, Kristensen GB, Skovlund E, Pettersen EO, Abeler VM (2001)
    Histologic subtype has minor importance for overall survival in patients with adenocarcinoma of the uterine cervix: a population-based study of prognostic factors in 505 patients with nonsquamous cell carcinomas of the cervix
    Cancer, 92 (9), 2471-83
    DOI 10.1002/1097-0142(20011101)92:9<2471::aid-cncr1597>;2-k, PubMed 11745305
  2. Baekelandt M, Lehne G, Tropé CG, Szántó I, Pfeiffer P, Gustavssson B, Kristensen GB (2001)
    Phase I/II trial of the multidrug-resistance modulator valspodar combined with cisplatin and doxorubicin in refractory ovarian cancer
    J Clin Oncol, 19 (12), 2983-93
    DOI 10.1200/JCO.2001.19.12.2983, PubMed 11408493
  3. Dai H, Holm R, Kristensen GB, Abeler VM, Børresen-Dale AL, Helland A (2001)
    Fibroblast growth factor receptor 3 (FGFR3) - analyses of the S249C mutation and protein expression in primary cervical carcinomas
    Anal Cell Pathol, 23 (2), 45-9
    DOI 10.1155/2001/521873, PubMed 11904459
  4. Davidson B, Goldberg I, Berner A, Nesland JM, Givant-Horwitz V, Bryne M, Risberg B, Kristensen GB, Tropé CG, Kopolovic J, Reich R (2001)
    Expression of membrane-type 1, 2, and 3 matrix metalloproteinases messenger RNA in ovarian carcinoma cells in serous effusions
    Am J Clin Pathol, 115 (4), 517-24
    DOI 10.1309/B1YX-L8DB-TGY1-7905, PubMed 11293899
  5. Davidson B, Lazarovici P, Ezersky A, Nesland JM, Berner A, Risberg B, Tropé CG, Kristensen GB, Goscinski M, van de Putte G, Reich R (2001)
    Expression levels of the nerve growth factor receptors TrkA and p75 in effusions and solid tumors of serous ovarian carcinoma patients
    Clin Cancer Res, 7 (11), 3457-64
    PubMed 11705863
  6. Davidson B, Reich R, Berner A, Givant-Horwitz V, Goldberg I, Risberg B, Kristensen GB, Trope CG, Bryne M, Kopolovic J, Nesland JM (2001)
    Ovarian carcinoma cells in serous effusions show altered MMP-2 and TIMP-2 mRNA levels
    Eur J Cancer, 37 (16), 2040-9
    DOI 10.1016/s0959-8049(01)00235-0, PubMed 11597382
  7. Davidson B, Risberg B, Berner A, Nesland JM, Tropé CG, Kristensen GB, Bryne M, Goscinski M, van de Putte G, Flørenes VA (2001)
    Expression of cell cycle proteins in ovarian carcinoma cells in serous effusions-biological and prognostic implications
    Gynecol Oncol, 83 (2), 249-56
    DOI 10.1006/gyno.2001.6388, PubMed 11606079
  8. Lyng H, Sundfor K, Rofstad EK (2001)
    Serial changes in tumor oxygenation during the early phase of radiation therapy in cervical cancer - Are we quantitating hypoxia change? Response
    Int. J. Radiat. Oncol. Biol. Phys., 49 (1), 285-289
  9. Makar AP, Scheistroen M, van den Weyngaert D, Tropé CG (2001)
    Surgical management of stage I and II vulvar cancer: the role of the sentinel node biopsy. Review of literature
    Int J Gynecol Cancer, 11 (4), 255-62
    DOI 10.1046/j.1525-1438.2001.011004255.x, PubMed 11520362
  10. Makar AP, Tropé C (2001)
    Fertility preservation in gynecologic cancer
    Acta Obstet Gynecol Scand, 80 (9), 794-802
    DOI 10.1034/j.1600-0412.2001.080009794.x, PubMed 11531628
  11. Tropé C, Kristensen G, Kisic J, Kaern J (2001)
    Long-term results from a phase II study of paclitaxel combined with doxorubicin in recurrent platinum refractory ovarian cancer
    Eur J Gynaecol Oncol, 22 (3), 223-7
    PubMed 11501778
  12. Tropé C, Kristensen GB, Abeler VM (2001)
    Clear-cell and papillary serous cancer: treatment options
    Best Pract Res Clin Obstet Gynaecol, 15 (3), 433-46
    DOI 10.1053/beog.2000.0187, PubMed 11476564

Publications 2000

  1. Alfsen GC, Thoresen SO, Kristensen GB, Skovlund E, Abeler VM (2000)
    Histopathologic subtyping of cervical adenocarcinoma reveals increasing incidence rates of endometrioid tumors in all age groups: a population based study with review of all nonsquamous cervical carcinomas in Norway from 1966 to 1970, 1976 to 1980, and 1986 to 1990
    Cancer, 89 (6), 1291-9
    DOI 10.1002/1097-0142(20000915)89:6<1291::AID-CNCR14>3.0.CO;2-O, PubMed 11002225
  2. Baekelandt M, Holm R, Nesland JM, Tropé CG, Kristensen GB (2000)
    Expression of apoptosis-related proteins is an independent determinant of patient prognosis in advanced ovarian cancer
    J Clin Oncol, 18 (22), 3775-81
    DOI 10.1200/JCO.2000.18.22.3775, PubMed 11078490
  3. Baekelandt M, Jorunn Nesbakken A, Kristensen GB, Tropé CG, Abeler VM (2000)
    Carcinoma of the fallopian tube
    Cancer, 89 (10), 2076-84
    PubMed 11066048
  4. Baekelandt MM, Holm R, Nesland JM, Tropé CG, Kristensen GB (2000)
    P-glycoprotein expression is a marker for chemotherapy resistance and prognosis in advanced ovarian cancer
    Anticancer Res, 20 (2B), 1061-7
    PubMed 10810398
  5. Davidson B, Berner A, Nesland JM, Risberg B, Berner HS, Tropè CG, Kristensen GB, Bryne M, Ann Florenes V (2000)
    E-cadherin and alpha-, beta-, and gamma-catenin protein expression is up-regulated in ovarian carcinoma cells in serous effusions
    J Pathol, 192 (4), 460-9
    DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH726>3.0.CO;2-M, PubMed 11113863
  6. Davidson B, Berner A, Nesland JM, Risberg B, Kristensen GB, Tropé CG, Bryne M (2000)
    Carbohydrate antigen expression in primary tumors, metastatic lesions, and serous effusions from patients diagnosed with epithelial ovarian carcinoma: evidence of up-regulated Tn and Sialyl Tn antigen expression in effusions
    Hum Pathol, 31 (9), 1081-7
    DOI 10.1053/hupa.2000.9776, PubMed 11014575
  7. Helland A, Kraggerud SM, Kristensen GB, Holm R, Abeler VM, Huebner K, Borresen-Dale AL, Lothe RA (2000)
    Primary cervical carcinomas show 2 common regions of deletion at 3P, 1 within the FHIT gene: evaluation of allelic imbalance at FHIT, RB1 and TP53 in relation to survival
    Int J Cancer, 88 (2), 217-22
    DOI 10.1002/1097-0215(20001015)88:2<217::aid-ijc11>;2-i, PubMed 11004671
  8. Kraggerud SM, Szymanska J, Abeler VM, Kaern J, Eknaes M, Heim S, Teixeira MR, Tropé CG, Peltomäki P, Lothe RA (2000)
    DNA copy number changes in malignant ovarian germ cell tumors
    Cancer Res, 60 (11), 3025-30
    PubMed 10850452
  9. Lyng H, Sundfør K, Rofstad EK (2000)
    Changes in tumor oxygen tension during radiotherapy of uterine cervical cancer: relationships to changes in vascular density, cell density, and frequency of mitosis and apoptosis
    Int J Radiat Oncol Biol Phys, 46 (4), 935-46
    DOI 10.1016/s0360-3016(99)00497-6, PubMed 10705016
  10. Lyng H, Sundfør K, Tropé C, Rofstad EK (2000)
    Disease control of uterine cervical cancer: relationships to tumor oxygen tension, vascular density, cell density, and frequency of mitosis and apoptosis measured before treatment and during radiotherapy
    Clin Cancer Res, 6 (3), 1104-12
    PubMed 10741740
  11. Makar AP, Kisic J, Tropé CG (2000)
    Controversies in surgical management of advanced ovarian cancer (stage III-IV)
    Eur J Gynaecol Oncol, 21 (5), 449-60
    PubMed 11198031
  12. Paulsen T, Marth C, Kaern J, Nustad K, Kristensen GB, Tropé C (2000)
    Effects of paclitaxel on CA-125 serum levels in ovarian cancer patients
    Gynecol Oncol, 76 (3), 326-30
    DOI 10.1006/gyno.1999.5699, PubMed 10684705
  13. Tropé C (2000)
    [Ovarian cancer screening of high risk groups]
    Tidsskr Nor Laegeforen, 120 (18), 2191
    PubMed 11006746
  14. Tropé C, Kaern J, Hogberg T, Abeler V, Hagen B, Kristensen G, Onsrud M, Pettersen E, Rosenberg P, Sandvei R, Sundfor K, Vergote I (2000)
    Randomized study on adjuvant chemotherapy in stage I high-risk ovarian cancer with evaluation of DNA-ploidy as prognostic instrument
    Ann Oncol, 11 (3), 281-8
    DOI 10.1023/a:1008399414923, PubMed 10811493
  15. Tropé C, Marth C, Kaern J (2000)
    Tamoxifen in the treatment of recurrent ovarian carcinoma
    Eur J Cancer, 36 Suppl 4, S59-61
    DOI 10.1016/s0959-8049(00)00228-8, PubMed 11056321
  16. Tropé CG, Kisic J, Vergote I (2000)
    Prognostic factors in platinum-resistant ovarian carcinoma treated with ifosfamide-etoposide
    Eur J Gynaecol Oncol, 21 (3), 255-9
    PubMed 10949388
  17. Tropé CG, Kristensen G, Makar A (2000)
    Surgery for borderline tumor of the ovary
    Semin Surg Oncol, 19 (1), 69-75
    DOI 10.1002/1098-2388(200007/08)19:1<69::aid-ssu11>;2-e, PubMed 10883027
  18. Vergote I, Rustin GJ, Eisenhauer EA, Kristensen GB, Pujade-Lauraine E, Parmar MK, Friedlander M, Jakobsen A, Vermorken JB (2000)
    Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup
    J Natl Cancer Inst, 92 (18), 1534-5
    DOI 10.1093/jnci/92.18.1534, PubMed 10995813
Page visits: 7104